UNITED STATES |
SECURITIES AND EXCHANGE COMMISSION |
Washington, D.C. 20549 |
FORM 10-Q |
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
WEST PHARMACEUTICAL SERVICES, INC. (Exact name of registrant as specified in its charter) |
Pennsylvania | 23-1210010 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |
530 Herman O. West Drive, Exton, PA | 19341-0645 |
(Address of principal executive offices) | (Zip Code) |
Large accelerated filer | þ | Accelerated filer | o | |
Non-accelerated filer | o | (Do not check if a smaller reporting company) | Smaller reporting company | o |
Page | ||
FINANCIAL STATEMENTS (UNAUDITED) | ||
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | ||
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | ||
CONTROLS AND PROCEDURES | ||
LEGAL PROCEEDINGS | ||
RISK FACTORS | ||
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS | ||
EXHIBITS | ||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2016 | 2015 | 2016 | 2015 | ||||||||||||
Net sales | $ | 376.7 | $ | 344.5 | $ | 1,126.8 | $ | 1,040.1 | |||||||
Cost of goods and services sold | 255.6 | 236.2 | 749.1 | 703.9 | |||||||||||
Gross profit | 121.1 | 108.3 | 377.7 | 336.2 | |||||||||||
Research and development | 9.0 | 8.5 | 27.2 | 24.1 | |||||||||||
Selling, general and administrative expenses | 58.3 | 54.6 | 178.9 | 170.6 | |||||||||||
Other expense (Note 12) | 2.5 | 48.7 | 29.1 | 58.1 | |||||||||||
Operating profit (loss) | 51.3 | (3.5 | ) | 142.5 | 83.4 | ||||||||||
Interest expense | 2.2 | 3.7 | 6.7 | 11.2 | |||||||||||
Interest income | 0.2 | 0.5 | 0.8 | 1.3 | |||||||||||
Income (loss) before income taxes | 49.3 | (6.7 | ) | 136.6 | 73.5 | ||||||||||
Income tax expense (benefit) | 14.4 | (6.6 | ) | 38.3 | 15.1 | ||||||||||
Equity in net income of affiliated companies | 2.7 | 1.6 | 6.2 | 3.8 | |||||||||||
Net income | $ | 37.6 | $ | 1.5 | $ | 104.5 | $ | 62.2 | |||||||
Net income per share: | |||||||||||||||
Basic | $ | 0.51 | $ | 0.02 | $ | 1.43 | $ | 0.86 | |||||||
Diluted | $ | 0.50 | $ | 0.02 | $ | 1.40 | $ | 0.85 | |||||||
Weighted average shares outstanding: | |||||||||||||||
Basic | 73.3 | 72.2 | 73.0 | 71.9 | |||||||||||
Diluted | 75.0 | 73.9 | 74.7 | 73.6 | |||||||||||
Dividends declared per share | $ | 0.13 | $ | 0.12 | $ | 0.37 | $ | 0.34 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
2016 | 2015 | 2016 | 2015 | ||||||||||||
Net income | $ | 37.6 | $ | 1.5 | $ | 104.5 | $ | 62.2 | |||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||
Foreign currency translation adjustments | 5.9 | (13.5 | ) | 15.9 | (58.0 | ) | |||||||||
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.3, $11.4, $0.9 and $12.3, respectively | 0.6 | 19.7 | 2.2 | 21.3 | |||||||||||
Net gains (losses) on derivatives, net of tax of $(0.1), $(0.1), $0.4 and $0.7, respectively | — | (0.4 | ) | 0.7 | 1.5 | ||||||||||
Other comprehensive income (loss), net of tax | 6.5 | 5.8 | 18.8 | (35.2 | ) | ||||||||||
Comprehensive income | $ | 44.1 | $ | 7.3 | $ | 123.3 | $ | 27.0 |
September 30, 2016 | December 31, 2015 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 205.9 | $ | 274.6 | |||
Accounts receivable, net | 209.5 | 181.4 | |||||
Inventories | 201.1 | 181.1 | |||||
Other current assets | 41.6 | 36.6 | |||||
Total current assets | 658.1 | 673.7 | |||||
Property, plant and equipment | 1,551.1 | 1,440.3 | |||||
Less: accumulated depreciation and amortization | 778.4 | 719.3 | |||||
Property, plant and equipment, net | 772.7 | 721.0 | |||||
Investments in affiliated companies | 81.4 | 61.3 | |||||
Goodwill | 105.2 | 104.6 | |||||
Deferred income taxes | 70.7 | 70.5 | |||||
Intangible assets, net | 24.4 | 37.6 | |||||
Other noncurrent assets | 22.8 | 26.4 | |||||
Total Assets | $ | 1,735.3 | $ | 1,695.1 | |||
LIABILITIES AND EQUITY | |||||||
Current liabilities: | |||||||
Notes payable and other current debt | $ | 2.6 | $ | 69.3 | |||
Accounts payable | 99.0 | 119.8 | |||||
Pension and other postretirement benefits | 5.7 | 5.6 | |||||
Accrued salaries, wages and benefits | 58.9 | 53.0 | |||||
Income taxes payable | 3.2 | 12.8 | |||||
Other current liabilities | 67.4 | 53.8 | |||||
Total current liabilities | 236.8 | 314.3 | |||||
Long-term debt | 228.6 | 228.9 | |||||
Deferred income taxes | 15.2 | 12.4 | |||||
Pension and other postretirement benefits | 62.5 | 62.0 | |||||
Other long-term liabilities | 49.9 | 53.6 | |||||
Total Liabilities | 593.0 | 671.2 | |||||
Commitments and contingencies (Note 14) | |||||||
Equity: | |||||||
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding | — | — | |||||
Common stock, $0.25 par value; 100.0 million shares authorized; issued: 73.5 million and 72.4 million; outstanding: 73.2 million and 72.3 million | 18.4 | 18.1 | |||||
Capital in excess of par value | 247.6 | 207.8 | |||||
Retained earnings | 1,041.9 | 964.6 | |||||
Accumulated other comprehensive loss | (143.8 | ) | (162.6 | ) | |||
Treasury stock, at cost (0.3 million and 0.1 million shares) | (21.8 | ) | (4.0 | ) | |||
Total Equity | 1,142.3 | 1,023.9 | |||||
Total Liabilities and Equity | $ | 1,735.3 | $ | 1,695.1 |
Common Stock | Capital in Excess of Par Value | Treasury Stock | Retained earnings | Accumulated other comprehensive (loss) income | Total | |||||||||||||||||||||
Shares | Amount | |||||||||||||||||||||||||
Balance, December 31, 2015 | 72.4 | $ | 18.1 | $ | 207.8 | $ | (4.0 | ) | $ | 964.6 | $ | (162.6 | ) | $ | 1,023.9 | |||||||||||
Net income | — | — | — | — | 104.5 | — | 104.5 | |||||||||||||||||||
Stock-based compensation | — | — | 12.7 | 0.3 | — | — | 13.0 | |||||||||||||||||||
Shares issued under stock plans | 1.2 | 0.3 | 16.9 | 8.7 | — | — | 25.9 | |||||||||||||||||||
Shares purchased under share repurchase program | — | — | — | (26.8 | ) | — | — | (26.8 | ) | |||||||||||||||||
Shares repurchased for employee tax withholdings | (0.1 | ) | — | (3.7 | ) | — | — | — | (3.7 | ) | ||||||||||||||||
Excess tax benefits from employee stock plans | — | — | 13.9 | — | — | — | 13.9 | |||||||||||||||||||
Dividends declared | — | — | — | — | (27.2 | ) | — | (27.2 | ) | |||||||||||||||||
Other comprehensive income, net of tax | — | — | — | — | — | 18.8 | 18.8 | |||||||||||||||||||
Balance, September 30, 2016 | 73.5 | $ | 18.4 | $ | 247.6 | $ | (21.8 | ) | $ | 1,041.9 | $ | (143.8 | ) | $ | 1,142.3 |
Nine Months Ended September 30, | |||||||
2016 | 2015 | ||||||
Cash flows from operating activities: | |||||||
Net income | $ | 104.5 | $ | 62.2 | |||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Depreciation | 65.9 | 63.6 | |||||
Amortization | 2.0 | 3.0 | |||||
Stock-based compensation | 14.1 | 24.4 | |||||
Non-cash restructuring charges | 15.9 | — | |||||
Pension settlement charge | — | 49.0 | |||||
Other non-cash items, net | (3.7 | ) | (2.7 | ) | |||
Changes in assets and liabilities | (51.1 | ) | (55.1 | ) | |||
Net cash provided by operating activities | 147.6 | 144.4 | |||||
Cash flows from investing activities: | |||||||
Capital expenditures | (122.7 | ) | (86.8 | ) | |||
Purchase of cost-method investment | (8.4 | ) | — | ||||
Other, net | 2.0 | 1.2 | |||||
Net cash used in investing activities | (129.1 | ) | (85.6 | ) | |||
Cash flows from financing activities: | |||||||
Borrowings under revolving credit agreements | — | 57.4 | |||||
Repayments under revolving credit agreements | — | (57.4 | ) | ||||
Repayments of long-term debt | (69.2 | ) | (26.7 | ) | |||
Dividend payments | (26.2 | ) | (23.7 | ) | |||
Excess tax benefits from employee stock plans | 13.9 | 4.2 | |||||
Shares purchased under share repurchase program | (26.8 | ) | — | ||||
Shares repurchased for employee tax withholdings | (3.7 | ) | (5.6 | ) | |||
Proceeds from exercise of stock options and stock appreciation rights | 21.8 | 9.7 | |||||
Employee stock purchase plan contributions | 2.8 | 2.3 | |||||
Contingent consideration payments | (0.1 | ) | (0.1 | ) | |||
Net cash used in financing activities | (87.5 | ) | (39.9 | ) | |||
Effect of exchange rates on cash | 0.3 | (17.4 | ) | ||||
Net (decrease) increase in cash and cash equivalents | (68.7 | ) | 1.5 | ||||
Cash and cash equivalents at beginning of period | 274.6 | 255.3 | |||||
Cash and cash equivalents at end of period | $ | 205.9 | $ | 256.8 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
(In millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Net income | $ | 37.6 | $ | 1.5 | $ | 104.5 | $ | 62.2 | |||||||
Weighted average common shares outstanding | 73.3 | 72.2 | 73.0 | 71.9 | |||||||||||
Dilutive effect of equity awards, based on the treasury stock method | 1.7 | 1.7 | 1.7 | 1.7 | |||||||||||
Weighted average shares assuming dilution | 75.0 | 73.9 | 74.7 | 73.6 |
($ in millions) | September 30, 2016 | December 31, 2015 | |||||
Raw materials | $ | 82.5 | $ | 74.4 | |||
Work in process | 32.2 | 30.1 | |||||
Finished goods | 86.4 | 76.6 | |||||
$ | 201.1 | $ | 181.1 |
($ in millions) | September 30, 2016 | December 31, 2015 | |||||
Euro note B, due February 27, 2016 (4.38%) | $ | — | $ | 66.8 | |||
Term loan, due January 1, 2018 (1.74%) | 35.4 | 37.1 | |||||
Note payable, due December 31, 2019 | 0.2 | 0.2 | |||||
Revolving credit facility, due October 15, 2020 (1.71%) | 28.5 | 27.1 | |||||
Series A notes, due July 5, 2022 (3.67%) | 42.0 | 42.0 | |||||
Series B notes, due July 5, 2024 (3.82%) | 53.0 | 53.0 | |||||
Series C notes, due July 5, 2027 (4.02%) | 73.0 | 73.0 | |||||
Total debt | 232.1 | 299.2 | |||||
Less: current portion of long-term debt | 2.6 | 69.3 | |||||
Less: unamortized debt issuance costs | 0.9 | 1.0 | |||||
Long-term debt, net | $ | 228.6 | $ | 228.9 |
Amount of Gain (Loss) Recognized in OCI for | Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for | Location of (Gain) Loss Reclassified from Accumulated OCI into Income | |||||||||||||||
Three Months Ended September 30, | Three Months Ended September 30, | ||||||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||||
Cash Flow Hedges: | |||||||||||||||||
Foreign currency hedge contracts | $ | — | $ | — | $ | — | $ | (0.4 | ) | Net sales | |||||||
Foreign currency hedge contracts | (0.3 | ) | (0.3 | ) | — | — | Cost of goods and services sold | ||||||||||
Interest rate swap contracts | — | (0.1 | ) | 0.2 | 0.3 | Interest expense | |||||||||||
Forward treasury locks | — | — | 0.1 | 0.1 | Interest expense | ||||||||||||
Total | $ | (0.3 | ) | $ | (0.4 | ) | $ | 0.3 | $ | — | |||||||
Net Investment Hedges: | |||||||||||||||||
Foreign currency-denominated debt | $ | (0.2 | ) | $ | (0.8 | ) | $ | — | $ | — | Other expense | ||||||
Total | $ | (0.2 | ) | $ | (0.8 | ) | $ | — | $ | — |
Amount of Gain (Loss) Recognized in OCI for | Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for | Location of (Gain) Loss Reclassified from Accumulated OCI into Income | |||||||||||||||
Nine Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||||
Cash Flow Hedges: | |||||||||||||||||
Foreign currency hedge contracts | $ | (0.3 | ) | $ | 1.4 | $ | 0.1 | $ | (1.1 | ) | Net sales | ||||||
Foreign currency hedge contracts | 0.3 | 0.3 | — | — | Cost of goods and services sold | ||||||||||||
Interest rate swap contracts | (0.2 | ) | (0.4 | ) | 0.6 | 1.1 | Interest expense | ||||||||||
Forward treasury locks | — | — | 0.2 | 0.2 | Interest expense | ||||||||||||
Total | $ | (0.2 | ) | $ | 1.3 | $ | 0.9 | $ | 0.2 | ||||||||
Net Investment Hedges: | |||||||||||||||||
Foreign currency-denominated debt | $ | (1.3 | ) | $ | 4.7 | $ | — | $ | — | Other expense | |||||||
Total | $ | (1.3 | ) | $ | 4.7 | $ | — | $ | — |
• | Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. |
• | Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. |
• | Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. |
Balance at | Basis of Fair Value Measurements | ||||||||||||||
($ in millions) | September 30, 2016 | Level 1 | Level 2 | Level 3 | |||||||||||
Assets: | |||||||||||||||
Deferred compensation assets | $ | 6.4 | $ | 6.4 | $ | — | $ | — | |||||||
Foreign currency contracts | 0.6 | — | 0.6 | — | |||||||||||
$ | 7.0 | $ | 6.4 | $ | 0.6 | $ | — | ||||||||
Liabilities: | |||||||||||||||
Contingent consideration | $ | 7.8 | $ | — | $ | — | $ | 7.8 | |||||||
Deferred compensation liabilities | 6.8 | 6.8 | — | — | |||||||||||
Interest rate swap contract | 1.3 | — | 1.3 | — | |||||||||||
Foreign currency contracts | 0.1 | — | 0.1 | — | |||||||||||
$ | 16.0 | $ | 6.8 | $ | 1.4 | $ | 7.8 |
Balance at | Basis of Fair Value Measurements | ||||||||||||||
($ in millions) | December 31, 2015 | Level 1 | Level 2 | Level 3 | |||||||||||
Assets: | |||||||||||||||
Deferred compensation assets | $ | 6.8 | $ | 6.8 | $ | — | $ | — | |||||||
Foreign currency contracts | 0.2 | — | 0.2 | — | |||||||||||
$ | 7.0 | $ | 6.8 | $ | 0.2 | $ | — | ||||||||
Liabilities: | |||||||||||||||
Contingent consideration | $ | 6.0 | $ | — | $ | — | $ | 6.0 | |||||||
Deferred compensation liabilities | 8.8 | 8.8 | — | — | |||||||||||
Interest rate swap contract | 2.0 | — | 2.0 | — | |||||||||||
Foreign currency contracts | 0.2 | — | 0.2 | — | |||||||||||
$ | 17.0 | $ | 8.8 | $ | 2.2 | $ | 6.0 |
Nine Months Ended September 30, | |||||||
2016 | 2015 | ||||||
Beginning balance | $ | 6.0 | $ | 5.0 | |||
Increase in fair value recorded in earnings | 1.9 | 0.8 | |||||
Payments | (0.1 | ) | (0.1 | ) | |||
Ending balance | $ | 7.8 | $ | 5.7 |
Pension benefits | Other retirement benefits | Total | |||||||||||||||||||||
2016 | 2015 | 2016 | 2015 | 2016 | 2015 | ||||||||||||||||||
Service cost | $ | 2.3 | $ | 2.5 | $ | 0.1 | $ | 0.1 | $ | 2.4 | $ | 2.6 | |||||||||||
Interest cost | 2.7 | 3.4 | 0.1 | 0.1 | 2.8 | 3.5 | |||||||||||||||||
Expected return on assets | (3.1 | ) | (4.9 | ) | — | — | (3.1 | ) | (4.9 | ) | |||||||||||||
Amortization of prior service credit | (0.3 | ) | (0.3 | ) | — | — | (0.3 | ) | (0.3 | ) | |||||||||||||
Recognized actuarial losses (gains) | 1.3 | 1.6 | (0.3 | ) | (0.4 | ) | 1.0 | 1.2 | |||||||||||||||
Settlements | — | 49.0 | — | — | — | 49.0 | |||||||||||||||||
Net periodic benefit cost | $ | 2.9 | $ | 51.3 | $ | (0.1 | ) | $ | (0.2 | ) | $ | 2.8 | $ | 51.1 |
Pension benefits | Other retirement benefits | Total | |||||||||||||||||||||
2016 | 2015 | 2016 | 2015 | 2016 | 2015 | ||||||||||||||||||
U.S. plans | $ | 2.3 | $ | 50.7 | $ | (0.1 | ) | $ | (0.2 | ) | $ | 2.2 | $ | 50.5 | |||||||||
International plans | 0.6 | 0.6 | — | — | 0.6 | 0.6 | |||||||||||||||||
Net periodic benefit cost | $ | 2.9 | $ | 51.3 | $ | (0.1 | ) | $ | (0.2 | ) | $ | 2.8 | $ | 51.1 |
Pension benefits | Other retirement benefits | Total | |||||||||||||||||||||
2016 | 2015 | 2016 | 2015 | 2016 | 2015 | ||||||||||||||||||
Service cost | $ | 7.6 | $ | 8.0 | $ | 0.4 | $ | 0.4 | $ | 8.0 | $ | 8.4 | |||||||||||
Interest cost | 7.9 | 11.2 | 0.3 | 0.3 | 8.2 | 11.5 | |||||||||||||||||
Expected return on assets | (9.5 | ) | (16.3 | ) | — | — | (9.5 | ) | (16.3 | ) | |||||||||||||
Amortization of transition obligation | 0.1 | 0.1 | — | — | 0.1 | 0.1 | |||||||||||||||||
Amortization of prior service credit | (1.0 | ) | (1.0 | ) | — | — | (1.0 | ) | (1.0 | ) | |||||||||||||
Recognized actuarial losses (gains) | 3.6 | 4.8 | (1.0 | ) | (1.1 | ) | 2.6 | 3.7 | |||||||||||||||
Settlements | — | 49.0 | — | — | — | 49.0 | |||||||||||||||||
Net periodic benefit cost | $ | 8.7 | $ | 55.8 | $ | (0.3 | ) | $ | (0.4 | ) | $ | 8.4 | $ | 55.4 |
Pension benefits | Other retirement benefits | Total | |||||||||||||||||||||
2016 | 2015 | 2016 | 2015 | 2016 | 2015 | ||||||||||||||||||
U.S. plans | $ | 6.9 | $ | 53.8 | $ | (0.3 | ) | $ | (0.4 | ) | $ | 6.6 | $ | 53.4 | |||||||||
International plans | 1.8 | 2.0 | — | — | 1.8 | 2.0 | |||||||||||||||||
Net periodic benefit cost | $ | 8.7 | $ | 55.8 | $ | (0.3 | ) | $ | (0.4 | ) | $ | 8.4 | $ | 55.4 |
($ in millions) | Losses on cash flow hedges | Unrealized gains on investment securities | Defined benefit pension and other postretirement plans | Foreign currency translation | Total | ||||||||||||||
Balance, December 31, 2015 | $ | (3.1 | ) | $ | 5.4 | $ | (39.6 | ) | $ | (125.3 | ) | $ | (162.6 | ) | |||||
Other comprehensive income before reclassifications | (0.2 | ) | — | 1.1 | 15.9 | 16.8 | |||||||||||||
Amounts reclassified out | 0.9 | — | 1.1 | — | 2.0 | ||||||||||||||
Other comprehensive income, net of tax | 0.7 | — | 2.2 | 15.9 | 18.8 | ||||||||||||||
Balance, September 30, 2016 | $ | (2.4 | ) | $ | 5.4 | $ | (37.4 | ) | $ | (109.4 | ) | $ | (143.8 | ) |
Three Months Ended September 30, | Nine Months Ended September 30, | Location on Statement of Income | ||||||||||||||||
Detail of components | 2016 | 2015 | 2016 | 2015 | ||||||||||||||
(Losses) gains on cash flow hedges: | ||||||||||||||||||
Foreign currency contracts | $ | (0.1 | ) | $ | 0.4 | $ | (0.2 | ) | $ | 1.3 | Cost of goods and services sold | |||||||
Interest rate swap contracts | (0.3 | ) | (0.4 | ) | (1.0 | ) | (1.7 | ) | Interest expense | |||||||||
Forward treasury locks | (0.1 | ) | (0.1 | ) | (0.2 | ) | (0.3 | ) | Interest expense | |||||||||
Total before tax | (0.5 | ) | (0.1 | ) | (1.4 | ) | (0.7 | ) | ||||||||||
Tax expense | 0.2 | 0.1 | 0.5 | 0.5 | ||||||||||||||
Net of tax | $ | (0.3 | ) | $ | — | $ | (0.9 | ) | $ | (0.2 | ) | |||||||
Amortization of defined benefit pension and other postretirement plans: | ||||||||||||||||||
Transition obligation | $ | — | $ | — | $ | (0.1 | ) | $ | (0.1 | ) | (a) | |||||||
Prior service cost | 0.3 | 0.3 | 1.0 | 1.0 | (a) | |||||||||||||
Actuarial losses | (1.0 | ) | (50.2 | ) | (2.6 | ) | (52.7 | ) | (a) | |||||||||
Total before tax | (0.7 | ) | (49.9 | ) | (1.7 | ) | (51.8 | ) | ||||||||||
Tax expense | 0.2 | 18.5 | 0.6 | 19.1 | ||||||||||||||
Net of tax | $ | (0.5 | ) | $ | (31.4 | ) | $ | (1.1 | ) | $ | (32.7 | ) | ||||||
Total reclassifications for the period, net of tax | $ | (0.8 | ) | $ | (31.4 | ) | $ | (2.0 | ) | $ | (32.9 | ) |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Restructuring and related charges: | |||||||||||||||
Severance and post-employment benefits | $ | 1.4 | $ | — | $ | 7.8 | $ | — | |||||||
Asset-related charges | 0.9 | — | 15.9 | — | |||||||||||
Total restructuring and related charges | 2.3 | — | 23.7 | — | |||||||||||
Pension settlement charge | — | 49.0 | — | 49.0 | |||||||||||
Executive retirement and related costs | — | — | — | 10.9 | |||||||||||
Venezuela currency devaluation | — | — | 2.7 | — | |||||||||||
Development income | (0.4 | ) | (0.3 | ) | (1.2 | ) | (1.1 | ) | |||||||
Contingent consideration costs | — | 0.5 | 1.9 | 0.8 | |||||||||||
Other items | 0.6 | (0.5 | ) | 2.0 | (1.5 | ) | |||||||||
Total other expense | $ | 2.5 | $ | 48.7 | $ | 29.1 | $ | 58.1 |
($ in millions) | Severance and benefits | Asset-related charges | Total | ||||||
Balance, December 31, 2015 | $ | — | $ | — | $ | — | |||
Charges | 7.8 | 15.9 | 23.7 | ||||||
Cash payments | (1.6 | ) | — | (1.6 | ) | ||||
Non-cash asset write-downs | — | (15.9 | ) | (15.9 | ) | ||||
Balance, September 30, 2016 | $ | 6.2 | $ | — | $ | 6.2 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Net sales: | |||||||||||||||
Proprietary Products | $ | 298.1 | $ | 269.3 | $ | 899.9 | $ | 821.5 | |||||||
Contract-Manufactured Products | 79.0 | 75.5 | 227.8 | 219.4 | |||||||||||
Intersegment sales elimination | (0.4 | ) | (0.3 | ) | (0.9 | ) | (0.8 | ) | |||||||
Total net sales | $ | 376.7 | $ | 344.5 | $ | 1,126.8 | $ | 1,040.1 | |||||||
Operating profit (loss): | |||||||||||||||
Proprietary Products | $ | 57.5 | $ | 49.5 | $ | 185.6 | $ | 161.3 | |||||||
Contract-Manufactured Products | 8.9 | 8.3 | 25.6 | 22.7 | |||||||||||
Corporate | (12.8 | ) | (12.3 | ) | (42.3 | ) | (40.7 | ) | |||||||
Other unallocated items | (2.3 | ) | (49.0 | ) | (26.4 | ) | (59.9 | ) | |||||||
Total operating profit (loss) | $ | 51.3 | $ | (3.5 | ) | $ | 142.5 | $ | 83.4 | ||||||
Interest expense | 2.2 | 3.7 | 6.7 | 11.2 | |||||||||||
Interest income | 0.2 | 0.5 | 0.8 | 1.3 | |||||||||||
Income (loss) before income taxes | $ | 49.3 | $ | (6.7 | ) | $ | 136.6 | $ | 73.5 |
Three Months Ended September 30, | % Change | ||||||||||||
($ in millions) | 2016 | 2015 | As-Reported | Ex-Currency | |||||||||
Proprietary Products | $ | 298.1 | $ | 269.3 | 10.7 | % | 11.6 | % | |||||
Contract-Manufactured Products | 79.0 | 75.5 | 4.6 | % | 4.6 | % | |||||||
Intersegment sales elimination | (0.4 | ) | (0.3 | ) | — | — | |||||||
Consolidated net sales | $ | 376.7 | $ | 344.5 | 9.4 | % | 10.0 | % |
Nine Months Ended September 30, | % Change | ||||||||||||
($ in millions) | 2016 | 2015 | As-Reported | Ex-Currency | |||||||||
Proprietary Products | $ | 899.9 | $ | 821.5 | 9.5 | % | 11.1 | % | |||||
Contract-Manufactured Products | 227.8 | 219.4 | 3.8 | % | 3.7 | % | |||||||
Intersegment sales elimination | (0.9 | ) | (0.8 | ) | — | — | |||||||
Consolidated net sales | $ | 1,126.8 | $ | 1,040.1 | 8.3 | % | 9.5 | % |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Proprietary Products: | |||||||||||||||
Gross Profit | $ | 108.4 | $ | 95.6 | $ | 340.9 | $ | 301.3 | |||||||
Gross Profit Margin | 36.4 | % | 35.5 | % | 37.9 | % | 36.7 | % | |||||||
Contract-Manufactured Products: | |||||||||||||||
Gross Profit | $ | 12.7 | $ | 12.7 | $ | 36.8 | $ | 34.9 | |||||||
Gross Profit Margin | 16.0 | % | 16.8 | % | 16.1 | % | 15.9 | % | |||||||
Consolidated Gross Profit | $ | 121.1 | $ | 108.3 | $ | 377.7 | $ | 336.2 | |||||||
Consolidated Gross Profit Margin | 32.1 | % | 31.4 | % | 33.5 | % | 32.3 | % |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Proprietary Products | $ | 9.0 | $ | 8.5 | $ | 27.2 | $ | 24.1 | |||||||
Contract-Manufactured Products | — | — | — | — | |||||||||||
Consolidated R&D Costs | $ | 9.0 | $ | 8.5 | $ | 27.2 | $ | 24.1 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Proprietary Products | $ | 41.7 | $ | 38.0 | $ | 125.0 | $ | 117.8 | |||||||
Contract-Manufactured Products | 3.8 | 4.3 | 11.6 | 12.1 | |||||||||||
Corporate | 12.8 | 12.3 | 42.3 | 40.7 | |||||||||||
Consolidated SG&A costs | $ | 58.3 | $ | 54.6 | $ | 178.9 | $ | 170.6 | |||||||
SG&A as a % of net sales | 15.5 | % | 15.8 | % | 15.9 | % | 16.4 | % |
Expense (income) | Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Proprietary Products | $ | 0.2 | $ | (0.4 | ) | $ | 3.1 | $ | (1.9 | ) | |||||
Contract-Manufactured Products | — | 0.1 | (0.4 | ) | 0.1 | ||||||||||
Unallocated items | 2.3 | 49.0 | 26.4 | 59.9 | |||||||||||
Consolidated other expense | $ | 2.5 | $ | 48.7 | $ | 29.1 | $ | 58.1 |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Proprietary Products | $ | 57.5 | $ | 49.5 | $ | 185.6 | $ | 161.3 | |||||||
Contract-Manufactured Products | 8.9 | 8.3 | 25.6 | 22.7 | |||||||||||
Corporate | (12.8 | ) | (12.3 | ) | (42.3 | ) | (40.7 | ) | |||||||
Adjusted consolidated operating profit | $ | 53.6 | $ | 45.5 | $ | 168.9 | $ | 143.3 | |||||||
Adjusted consolidated operating profit margin | 14.2 | % | 13.2 | % | 15.0 | % | 13.8 | % | |||||||
Unallocated items | (2.3 | ) | (49.0 | ) | (26.4 | ) | (59.9 | ) | |||||||
Consolidated operating profit (loss) | $ | 51.3 | $ | (3.5 | ) | $ | 142.5 | $ | 83.4 | ||||||
Consolidated operating profit (loss) margin | 13.6 | % | (1.0 | )% | 12.6 | % | 8.0 | % |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
($ in millions) | 2016 | 2015 | 2016 | 2015 | |||||||||||
Interest expense | $ | 3.0 | $ | 4.0 | $ | 9.0 | $ | 12.2 | |||||||
Capitalized interest | (0.8 | ) | (0.3 | ) | (2.3 | ) | (1.0 | ) | |||||||
Interest income | (0.2 | ) | (0.5 | ) | (0.8 | ) | (1.3 | ) | |||||||
Interest expense, net | $ | 2.0 | $ | 3.2 | $ | 5.9 | $ | 9.9 |
($ in millions) | 2016 | 2015 | |||||
Net cash provided by operating activities | $ | 147.6 | $ | 144.4 | |||
Net cash used in investing activities | $ | (129.1 | ) | $ | (85.6 | ) | |
Net cash used in financing activities | $ | (87.5 | ) | $ | (39.9 | ) |
($ in millions) | September 30, 2016 | December 31, 2015 | |||||
Cash and cash equivalents | $ | 205.9 | $ | 274.6 | |||
Working capital | $ | 421.3 | $ | 359.4 | |||
Total debt | $ | 231.2 | $ | 298.2 | |||
Total equity | $ | 1,142.3 | $ | 1,023.9 | |||
Net debt-to-total invested capital | 2.2 | % | 2.3 | % |
• | sales demand and our ability to meet that demand; |
• | competition from other providers in our businesses, including customers’ in-house operations, and from lower-cost producers in emerging markets, which can impact unit volume, price and profitability; |
• | customers’ changing inventory requirements and manufacturing plans that alter existing orders or ordering patterns for the products we supply to them; |
• | the timing, regulatory approval and commercial success of customer products that incorporate our products and systems; |
• | whether customers agree to incorporate West’s products and delivery systems with their new and existing drug products, the ultimate timing and successful commercialization of those products and systems, which involves substantial evaluations of the functional, operational, clinical and economic viability of the Company’s products, and the rate, timing and success of regulatory approval for the drug products that incorporate the Company’s components and systems; |
• | the timely and adequate availability of filling capacity, which is essential to conducting definitive stability trials and the timing of first commercialization of customers’ products in Daikyo Crystal Zenith® prefilled syringes; |
• | average profitability, or mix, of products sold in any reporting period, including lower-than-expected sales growth of our high-value proprietary product offerings; |
• | maintaining or improving production efficiencies and overhead absorption; |
• | dependence on third-party suppliers and partners, some of which are single-source suppliers of critical materials and products, including our Japanese partner and affiliate, Daikyo; |
• | the loss of key personnel or highly-skilled employees; |
• | the availability and cost of skilled employees required to meet increased production, managerial, research and other needs, including professional employees and persons employed under collective bargaining agreements; |
• | interruptions or weaknesses in our supply chain, which could cause delivery delays or restrict the availability of raw materials, key purchased components and finished products; |
• | the successful and timely implementation of price increases necessary to offset rising production costs, including raw material prices, particularly petroleum-based raw materials; |
• | the cost and progress of development, regulatory approval and marketing of new products; |
• | our ability to obtain and maintain licenses in any jurisdiction in which we do business; |
• | the relative strength of USD in relation to other currencies, particularly the Euro, the Danish Krone, the Singapore Dollar, Yen, Venezuelan Bolivar, Colombian and Argentinian Peso, and Brazilian Real; and |
• | the potential adverse effects of global healthcare legislation on customer demand, product pricing and profitability. |
Period | Total number of shares purchased (1)(2) | Average price paid per share (1)(2) | Total number of shares purchased as part of publicly announced plans or programs (2) | Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (2) | |||||||||
July 1 – 31, 2016 | — | $ | — | — | 446,500 | ||||||||
August 1 – 31, 2016 | 80,190 | 81.40 | 80,000 | 366,500 | |||||||||
September 1 – 30, 2016 | 37,420 | 81.56 | 37,310 | 329,190 | |||||||||
Total | 117,610 | $ | 81.45 | 117,310 | 329,190 |
(1) | Includes 300 shares purchased on behalf of employees enrolled in the Non-Qualified Deferred Compensation Plan for Designated Employees (Amended and Restated Effective January 1, 2008). Under the plan, Company match contributions are delivered to the plan’s investment administrator, who then purchases shares in the open market and credits the shares to individual plan accounts. |
(2) | In December 2015, we announced a share repurchase program authorizing the repurchase of up to 700,000 shares of the Company’s common stock from time to time on the open market or in privately- negotiated transactions as permitted under the Securities Exchange Act of 1934 Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The program commenced on January 1, 2016 and is expected to be completed by December 31, 2016. During the third quarter of 2016, the Company purchased 117,310 shares of its common stock under this program at a cost of $9.6 million, or an average price of $81.46 per share. During the nine months ended September 30, 2016, the Company purchased 370,810 shares of its common stock under this program at a cost of $26.8 million, or an average price of $72.14 per share. |
Exhibit # | Description |
3.1 | Our Amended and Restated Articles of Incorporation are incorporated by reference from our Form 10-Q report for the quarter ended March 31, 2015. |
3.2 | Our Bylaws, as amended through May 5, 2015, are incorporated by reference from our Form 10-Q report for the quarter ended March 31, 2015. |
4.1 | Form of stock certificate for common stock is incorporated by reference from our annual report on Form 10-K dated May 6, 1999. |
4.2 | Article 5, 6, 8(c) and 9 of our Amended and Restated Articles of Incorporation are incorporated by reference from our Form 10-Q report for the quarter ended March 31, 2015. |
4.3 | Article I and V of our Bylaws, as amended through May 5, 2015, are incorporated by reference from our Form 10-Q report for the quarter ended March 31, 2015. |
4.4 | Instruments defining the rights of holders of long-term debt securities of West and its subsidiaries have been omitted. (1) |
10.1 | Employment Agreement, dated August 28, 2016 between David Montecalvo and us. |
10.2 | Agreement, dated August 16, 2016 to amend Agreement by and between the Goodyear Tire & Rubber Company and us. (2) |
31.1 | Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2 | Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1* | Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
32.2* | Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
101.INS | XBRL Instance Document |
101.SCH | XBRL Taxonomy Extension Schema Document |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
1. | Base Salary - Your base salary will be $370,000 per year payable on the Company’s normal payroll schedule. |
2. | Sign-On Awards. We will provide you with a sign-on cash bonus of $150,000 (“Sign-On Cash Bonus”). The Sign-On Cash Bonus will be paid with your first normal paycheck. The Sign-On Cash Bonus will be subject to a two-year repayment obligation in accordance with the repayment agreement attached to this Offer Letter as Exhibit I. |
3. | Relocation- You will be subject to our normal relocation policy attached as Exhibit II. Your relocation bonus payable on the first normal payroll date following your relocation to the Exton, Pennsylvania area, will be equal to two months’ of your then-current salary and will be subject to a one-year repayment obligation. As an exception to our policy, you will receive up to 90 calendar days of temporary housing. |
4. | Annual Incentive Compensation - Beginning in 2016, you will participate in West Pharmaceutical Services’ Annual Incentive Plan (“AIP”) with a target bonus of 60% of base salary as of the end of the year and payable in accordance with the terms of the AIP document except as specifically stated in this letter. Your award will be pro-rated based on your Start Date. |
5. | Long Term Incentive Compensation Long Term Incentive Compensation. You will be eligible to participate in West’s Long Term Incentive Plan (“LTIP”), which issues equity under the 2016 Omnibus Incentive Compensation Plan. The terms of your awards are summarized below. |
a. | Your first award will have a grant date fair value of $300,000 divided equally among stock options (vesting through February 23, 2020) and PSUs (2016-18 performance period), according to the terms in option and PSU award agreements attached hereto as part of Exhibit III. |
b. | You will also receive an LTIP award with an expected value of $400,000 split evenly among PSUs (three-year performance based vesting) and stock options (4-year time-vesting) at the Board’s annual grant meeting in February 2017. |
c. | The number of options is determined by reference to the Black-Scholes value on the date you commence employment with the Company. The exercise price of options shall be the fair market value (closing price) of the stock on the grant date. The number of PSUs is determined by reference to the fair market value (closing price) of our stock on the date you commence employment with the Company. |
6. | One-time Restricted Stock Unit (RSU) Award - You will receive a RSU award with a grant date fair value of $100,000, according to the terms in the RSU agreement attached hereto as part of Exhibit IV. The number of RSUs is determined by reference to the fair market value (closing price) of our stock on the date you commence employment with the Company. |
7. | Change in Control Agreement - You will receive our standard Change-in-Control agreement for executive officers, a form of which is attached hereto as Exhibit V. |
8. | Severance Agreement - On or before the second anniversary of your start date, you will be entitled to the severance benefits described in the Severance Agreement attached hereto as Exhibit VI. |
9. | Benefits - The Company offers excellent benefit programs to all of its employees. You will be eligible to participate in the employee benefit programs which include medical, dental, life insurance, 401(k) plan, a non-contributory cash balance pension plan (including a supplemental employees’ retirement plan), employee stock purchase program and deferred compensation program. There is a waiting period for some of these plans. Information regarding these plans is enclosed. |
10. | Vacation - We are able to offer you 20 working days (four weeks) of vacation annually. |
11. | Confidentiality Agreement - As a condition of employment, you will be required to sign our standard employee Confidentiality Agreement. |
• | “Cause” means (A) any willful failure by you to perform your duties or responsibilities or to comply with any valid and legal directives of your direct supervisor; (B) any act of fraud, embezzlement, theft or misappropriation of the funds of the Company by you, or your admission to or conviction of a felony or any crime involving moral turpitude, fraud, embezzlement, theft or misrepresentation; (C) your engagement in dishonesty, illegal conduct or misconduct that is materially injurious to the Company; (D) your breach of any material obligation under any written agreement between you and the Company; or (E) a material violation of a rule, policy, regulation or guideline imposed by the Company or a regulatory or self-regulatory body having jurisdiction over the Company. With respect to subsections (A), (D) and (E), the Company shall give you written notice of any alleged breach or violation of these subsections and afford you 30 days in which to remedy the condition. |
• | “Good Reason” means the occurrence of any of the following without your consent: (1) a material diminution in your base salary; (2) a material reduction in your duties, authority or responsibilities relative to your duties, authority, and responsibilities in effect immediately prior to such reduction; or (3) the relocation of your principal place of employment in a manner that lengthens by fifty (50) or more miles your one-way commuting distance to your place of employment; provided that a termination shall only be for Good Reason if: (a) within forty-five (45) calendar days of the initial existence of Good Reason, you provide written notice of Good Reason to the Company; (b) the Company does not remedy said Good Reason within thirty (30) calendar days of its receipt of such notice; and (c) you terminate employment within sixty (60) calendar days after the expiration of such 30-day remedy period. |
• | In the event that, within 24 months of my Start Date, I terminate my employment with the Company for any reason other than death, disability or Good Reason, or the Company terminates my employment for Cause, I agree to fully repay the Company the amount of the Sign-On Bonus paid by the Company. |
• | I am required to repay the Company for Sign-On Bonus immediately upon the applicable termination of employment. |
• | I grant an express lien and authorize the Company to deduct from any and all amounts otherwise payable by the Company to me at the time of termination including, wages, accrued, untaken vacation pay, and any severance payments, an amount equal to the Sign-On Bonus. The deduction of any amounts by the Company does not relieve me of the obligation to pay the Company the amount in excess of the amount deducted. |
• | In the event of my termination, I am responsible for any tax consequences resulting from the payment of the Sign-On Bonus or the repayment of the Sign-On Bonus by me to the Company. I will not be eligible for tax gross-up assistance. I accept responsibility for any tax liabilities, credits and/or deductions that I may incur as a result. |
• | I agree that in the event that I do not timely repay the amounts owed to the Company upon termination, interest will accrue on a monthly compounding basis at the prime rate of interest plus 1%. |
• | In the event that it shall become necessary for the Company to pursue its claims against me for the repayment of the Sign-On Bonus, any costs or expenses incurred by the Company including attorney’s fees, shall be my responsibility and any judgment entered against me with regard to the same should include the recovery of such costs and expenses. |
Stock Option Award: | 10,792 |
Expected Value | $150,000 |
Exercise Price | Total shares that may be purchased upon exercise | |
$71.79 | 10,792 |
Date | Portion of the option is exercisable |
September 26, 2016 (grant date) | 0 |
February 23, 2017 | 2,698 |
February 23, 2018 | 2,698 |
February 23, 2019 | 2,698 |
February 23, 2020 | 2,698 |
1. | You have reached age 57; |
2. | You have rendered 10 years of service to the Company and its affiliates; and |
3. | Your termination must not be due to “Cause” as defined in the Plan and not due to death or disability. |
1. | To the extent permitted by applicable law, you compete with the Company during the period of continued vesting as described in Exhibit II; |
2. | You fail to comply with any confidentiality agreements with the Company before or after your termination of employment;, |
3. | The Company determines that it could have terminated you for “Cause” due to facts or circumstances discovered after your termination of employment. |
• | if you die, the option will remain exercisable for one year from your date of death; |
• | if you terminate employment due to disability or a Qualifying Retirement, the option will remain exercisable until the Expiration Date; |
• | if your employment terminates for any reason other than a Qualifying Retirement, disability, death or removal for cause, the option will expire 90 days after the termination date; |
• | if we terminate your employment for cause, the option will expire on the commencement of business on your date of termination. |
• | Cash. You write a check to the Company for the exercise price, plus any applicable withholding taxes. |
• | Already owned shares. You may deliver or attest vested shares of common stock that you own with a fair market value equal to the exercise price, plus any applicable withholding taxes. |
• | Combination of shares and cash. You may use a combination of cash and stock. |
• | Reduction of proceeds. You may elect to have shares you would otherwise receive upon the exercise reduced by an amount equal to the total exercise cost divided by the fair market value of the shares at the time of your exercise. In effect, you would receive the “net” shares otherwise due to you after deducting for the exercise cost, plus applicable withholding taxes. |
1. | engage in competition with, or acquire a direct or indirect interest or an option to acquire such an interest in any Person engaged in competition with, the Company’s Business (other than an interest of not more than 5 percent of the outstanding stock of any publicly traded company); |
2. | serve as a director, officer, employee or consultant of, or furnish information to, or otherwise facilitate the efforts of, any Person engaged in competition with the Company’s Business; |
3. | solicit, employ, interfere with or attempt to entice away from the Company any employee who has been employed by the Company or a Subsidiary in an executive or supervisory capacity in connection with the conduct of the Company’s Business within one year prior to such solicitation, employment, interference or enticement; or |
4. | approach, solicit or deal with in competition with the Company or any Subsidiary any Person which at any time during the year immediately preceding the date of your Qualifying Retirement: |
a. | was a customer, client, supplier, agent or distributor of the Company or any Subsidiary; |
b. | was a customer, client, supplier, agent or distributor of the Company or any Subsidiary with whom employees reporting to or under your direct control had personal contact on behalf of the Company or any Subsidiary; or |
c. | was a Person with whom you had regular, substantial or a series of business dealings on behalf of the Company or any Subsidiary (whether or not a customer, client, supplier, agent or distributor of the Company or any Subsidiary). |
d. | As used in this Exhibit II, the capitalized terms shall have the meanings set forth below: |
i. | An “Affiliate” of any Person means any Person directly or indirectly controlling, controlled by or under common control with such Person. |
ii. | The “Company’s Business” means: (a) the manufacture and sale of stoppers, closures, containers, medical-device components and assemblies made from elastomers, metal and plastic for the health-care and consumer-products industries, and (b) any other business conducted by the Company or any of its Subsidiaries or Affiliates during the term of this Agreement and in which you have been actively involved. |
iii. | "Person” means an individual, a corporation, a partnership, an association, a trust or other entity or organization. |
iv. | “Subsidiary” has the meaning ascribed to the term by section 425(f) of the United States Internal Revenue Code of 1986, as amended. |
Target PSUs: | 2,091 |
Grant Date Fair Value: | $150,000 |
• | Average return on invested capital - also called “ROIC” - is measured by dividing the average of the Company’s net operating profit (without regard to taxes) over the performance period by the average outstanding equity plus debt over that period. |
• | Compounded annual revenue growth - also called “CAGR” - is the compound annual growth rate in net sales for the Company over the same period. |
Performance Range | CAGR | Average ROIC | |||
(applies to 50% of PSUs) | (applies to 50% of PSUs) | ||||
If CAGR is: | Then the payout as a % of Target is: | If ROIC is: | Then the payout as a % of Target is: | ||
Maximum: | 150% | 14.70% | 200% | 18.45% | 200% |
125% | 12.25% | 150% | 15.38% | 150% | |
110% | 10.78% | 120% | 13.53% | 120% | |
Target: | 100% | 9.80% | 100% | 12.30% | 100% |
85% | 8.33% | 75% | 10.46% | 75% | |
Threshold: | 70% | 6.86% | 50% | 8.61% | 50% |
< 70% | < 6.86% | -0- | <8.61% | -0- |
5. | engage in competition with, or acquire a direct or indirect interest or an option to acquire such an interest in any Person engaged in competition with, the Company’s Business (other than an interest of not more than 5 percent of the outstanding stock of any publicly traded company); |
6. | serve as a director, officer, employee or consultant of, or furnish information to, or otherwise facilitate the efforts of, any Person engaged in competition with the Company’s Business; |
7. | solicit, employ, interfere with or attempt to entice away from the Company any employee who has been employed by the Company or a Subsidiary in an executive or supervisory capacity in connection with the conduct of the Company’s Business within one year prior to such solicitation, employment, interference or enticement; or |
8. | approach, solicit or deal with in competition with the Company or any Subsidiary any Person which at any time during the year immediately preceding the date of your Qualifying Retirement: |
a. | was a customer, client, supplier, agent or distributor of the Company or any Subsidiary; |
b. | was a customer, client, supplier, agent or distributor of the Company or any Subsidiary with whom employees reporting to or under your direct control had personal contact on behalf of the Company or any Subsidiary; or |
c. | was a Person with whom you had regular, substantial or a series of business dealings on behalf of the Company or any Subsidiary (whether or not a customer, client, supplier, agent or distributor of the Company or any Subsidiary). |
d. | As used in this Exhibit II, the capitalized terms shall have the meanings set forth below: |
i. | An “Affiliate” of any Person means any Person directly or indirectly controlling, controlled by or under common control with such Person. |
ii. | The “Company’s Business” means: (a) the manufacture and sale of stoppers, closures, containers, medical-device components and assemblies made from elastomers, metal and plastic for the health-care and consumer-products industries, and (b) any other business conducted by the Company or any of its Subsidiaries or Affiliates during the term of this Agreement and in which you have been actively involved. |
iii. | "Person” means an individual, a corporation, a partnership, an association, a trust or other entity or organization. |
iv. | “Subsidiary” has the meaning ascribed to the term by section 425(f) of the United States Internal Revenue Code of 1986, as amended. |
AWARD TYPE | Grant Date Fair VALUE | NUMBER OF SHARES |
Restricted Stock Unit | $100,000 | 1,393 |
Date | Portion of the RSUs that are vested |
September 26, 2016 (grant date) | 0 |
September 26, 2021 | 1,393 |
1. | Definitions. As used in this Agreement, the following terms will have the meanings set forth below: |
(a) | An “Affiliate” of any Person means any Person directly or indirectly controlling, controlled by or under common control with such Person. |
(b) | “Change in Control” means a change in control of a nature that would be required to be reported in response to Item 5.01 of a Current Report on Form 8-K as in effect on the date of this Agreement pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, (the “Act”), provided, that, without limitation, a Change in Control shall be deemed to have occurred if: |
(i) | Any Person, other than: |
(1) | the Company, |
(2) | any Person who on the date hereof is a director or officer of the Company, or |
(3) | a trustee or fiduciary holding securities under an employee benefit plan of the Company, |
(ii) | During any period of two consecutive years during the term of this Agreement, individuals who at the beginning of such period constitute the Board of Directors of the Company cease for any reason to constitute at least a majority thereof, unless the election of each director who was not a director at the beginning of such period has been approved in advance by directors representing at least two-thirds of the directors then in office who were directors at the beginning of the period; or |
(iii) | The shareholders of the Company approve: (A) a plan of complete liquidation of the Company; or (B) an agreement for the sale or disposition of all or substantially all of the Company’s assets; or (C) a merger, consolidation, or reorganization of the Company with or involving any other corporation, other than a merger, consolidation, or reorganization (collectively, a “Non-Control Transaction”), that would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity), at least 50% of the combined voting power of the voting securities of the Company (or the surviving entity, or an entity which as a result of the Non-Control Transaction owns the Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) outstanding immediately after the Non-Control Transaction. |
(c) | “Code” means the Internal Revenue Code of 1986, as amended. |
(d) | “Constructive Termination” means the occurrence of any of the following events: |
(i) | The Company requires the Executive to assume any duties inconsistent with, or the Company makes a significant diminution or reduction in the nature or scope of the Executive’s authority or duties from, those assigned to or held by the Executive on the Effective Date; |
(ii) | A material reduction in the Executive’s annual salary or incentive compensation opportunities; |
(iii) | A relocation of the Executive’s site of employment to a location more than 50 miles from the Executive’s site of employment on the Effective Date; |
(iv) | The Company fails to provide the Executive with substantially the same fringe benefits that were provided to the Executive as of the Effective Date, or with a package of fringe benefits that, although one or more of such benefits may vary from those in effect as of the Effective Date, is substantially at least as beneficial to the Executive in all material respects as such fringe benefits taken as a whole; or |
(v) | A successor of the Company does not assume the Company’s obligations under this Agreement, expressly or as a matter of law. |
(1) | the Executive will have consented in writing or given a written waiver to the occurrence of any of the events enumerated in clauses (i) through (v) above; |
(2) | the Executive will have failed to give the Company written notice stating the Executive’s intention to claim Constructive Termination and the basis for that claim at least 10 days in advance of the effective date of the Executive’s resignation; or |
(3) | The event constituting a Constructive Termination has been cured by the Company prior to the effective date of the Executive’s resignation. |
(f) | “Payment” means |
(i) | any amount due or paid to the Executive under this Agreement, |
(ii) | any amount that is due or paid to the Executive under any plan, program or arrangement of the Company and any of its Subsidiaries, and |
(iii) | any amount or benefit that is due or payable to the Executive under this Agreement or under any plan, program or arrangement of the Company and any of its Subsidiaries not otherwise covered under clause (i) or (ii) hereof which must reasonably be taken into account under section 280G of the Code and the Regulations in determining the amount of the “parachute payments” received by the Executive, including, without limitation, any amounts which must be taken into account under the Code and Regulations as a result of (1) the acceleration of the vesting of any option, restricted stock or other equity award granted under any equity plan of the Company or otherwise, (2) the acceleration of the time at which any payment or benefit is receivable by the Executive or (3) any contingent severance or other amounts that are payable to the Executive. |
(g) | “Person” means an individual, a corporation, a partnership, an association, a trust or other entity or organization. |
(h) | “Regulations” means the proposed, temporary and final regulations under sections 4999, 280G or 409A of Code or any successor provisions thereto, as applicable. |
(i) | “Retirement Plan” means the West Pharmaceutical Services, Inc. Employees’ Retirement Plan and any successor plan thereto. |
(j) | “Savings/Deferred Comp Plan” means the Company’s 401(k) Plan, the Company’s Non-Qualified Deferred Compensation Plan for Designated Employees and any successor plans or other similar plans established from time to time that may allow executive officers to defer taxation of compensation. |
(k) | “Separation from Service” is the date on which the Executive ceases to be employed by the Company or any of its Subsidiaries or Affiliates for any reason and, to the extent that section 409A of the Code applies to the Payments under this agreement, shall be the date that the Executive incurs a “separation from service” as defined in that Code section and the Regulations. |
(l) | “Subsidiary” has the meaning ascribed to the term by section 425(f) of the Code. |
2. | Termination Following a Change in Control. |
(a) | Subject to Section 2(b), the Executive will be entitled to the benefits specified in Section 3 if, |
(i) | at any time within two years after a Change in Control has occurred, a Separation from Service occurs due to: (A) an involuntary termination of employment by the Company other than by reason of continuous willful misconduct to the detriment of the Company, or (B) as a result of the Executive’s resignation at any time following the Executive’s Constructive Termination, or |
(ii) | The Company signs an agreement, the consummation of which would result in the occurrence of a Change in Control, and then, a Separation from Service occurs due to (A) an involuntary termination of employment by the Company other than by reason of continuous willful misconduct to the detriment of the Company, or (B) the Executive’s resignation at any time following the Executive’s Constructive Termination occurring after the date of such agreement (and, if such agreement expires or is terminated prior to consummation, prior to the expiration or termination of such agreement). |
(b) | The Executive will not be entitled to the benefits specified in Section 3 if: |
(i) | the Executive’s employment terminates for any other reason, including, death, disability, voluntary resignation without a Constructive Termination or retirement under the Retirement Plan, or |
(ii) | the Executive is in breach of any of the Executive’s obligations under this Agreement before or following a Separation from Service. |
3. | Benefits Payable Upon Termination of Employment. Following a Separation from Service due to a termination of employment described in Section 2(a), the Executive will be entitled to the following benefits: |
(a) | Severance Compensation. the Executive will be entitled to severance compensation in an amount equal to two times the sum of |
(i) | the Executive’s highest annual base salary rate in effect during the year of the termination of the Executive’s employment, plus |
(ii) | the aggregate amount of the annual bonuses paid or payable to the Executive for the three fiscal years immediately preceding a Change in Control divided by the number of fiscal years as to which such bonuses were paid or payable; |
(b) | Equivalent of Vested Savings/Deferred Comp Plan Benefit. The Company will pay to the Executive the difference, if any, between |
(i) | the benefit the Executive would be entitled to receive under the Savings/Deferred Comp Plan if the Company’s contributions to the Savings/Deferred Comp Plan were fully vested upon the Separation from Service, and |
(ii) | the benefit the Executive is entitled to receive under the terms of the Savings/Deferred Comp Plan upon the Separation from Service. |
(c) | Unvested Equity Awards. All stock options, other equity-based awards and shares of the Company’s stock granted or awarded to the Executive pursuant to any Company compensation or benefit plan or arrangement, but which are unvested, will vest immediately upon the Separation from Service. The provisions of this Section 3(c) will supersede the terms of any such grant or award made to the Executive under any such plan or arrangement to the extent there is an inconsistency between the two. |
(d) | Employee and Executive Benefits. The Executive will be entitled to a continuation of all hospital, medical, dental, and similar insurance benefits not otherwise addressed in this Agreement in the same manner and amount to which the Executive was entitled on the date of a Change in Control or on the date of Constructive Termination of the Executive’s employment (whichever benefits are more favorable to the Executive) until the earlier of: |
(i) | a period of 36 months after the Separation from Service, |
(ii) | the Executive’s retirement under the Retirement Plan, or |
(iii) | the Executive’s eligibility for similar benefits with a new employer. |
(a) | No Duplication of Payments. If Executive is entitled to receive any Payment under this Agreement, he shall not also be entitled to receive severance payments under any other plan, program or agreement with the Company. |
4. | Excise Tax Limitation. |
(a) | Limitation. Notwithstanding any other provisions of this Agreement to the contrary, in the event that any Payments received or to be received by the Executive in connection with the Executive’s employment with the Company (or termination thereof) under this Agreement or otherwise would subject the Executive to the excise tax (plus any related interest and penalties) imposed under section 4999 of the Internal Revenue Code of 1986, as amended (the “Excise Tax”), and if the net-after tax amount (taking into account all applicable taxes payable by the Executive, including any Excise Tax) that the Executive would receive with respect to such payments or benefits does not exceed the net-after tax amount the Executive would receive if the amount of such payment and benefits were reduced to the maximum amount which could otherwise be payable to the Executive without the imposition of the Excise Tax, then, to the extent necessary to eliminate the imposition of the Excise Tax, (i) such cash Payments shall first be reduced (if necessary, to zero), then (ii) all non-cash Payments (other than those relating to equity and incentive plans) shall next be reduced (if necessary, to zero, and finally (iii) all other non-cash Payments relating to equity and incentive plans shall be reduced. |
(b) | Determination of Application of the Limitation. Subject to the provisions of Section 4(c), all determinations required under this Section 4 shall be made by the accounting firm that was the Company’s independent auditors immediately prior to the Change in Control (or, in default thereof, an accounting firm mutually agreed upon by the Company and the Executive) (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Executive and the Company within fifteen days of the Change in Control, |
(c) | Procedures. The Executive shall notify the Company in writing of any claim by the Internal Revenue Service that, if successful, would result in Payments that would be less on an after-tax basis than had those payments been limited under Section 4(a). Such notice shall be given as soon as practicable after the Executive knows of such claim and shall apprise the Company of the nature of the claim and the date on which the claim is requested to be paid. the Executive agrees not to pay the claim until the expiration of the thirty-day period following the date on which the Executive notifies the Company, or such shorter period ending on the date the Taxes with respect to such claim are due (the “Notice Period”). If the Company notifies the Executive in writing prior to the expiration of the Notice Period that it desires to contest the claim, the Executive shall: (i) give the Company any information reasonably requested by the Company relating to the claim; (ii) take such action in connection with the claim as the Company may reasonably request, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by the Company and reasonably acceptable to the Executive; (iii) cooperate with the Company in good faith in contesting the claim; and (iv) permit the Company to participate in any proceedings relating to the claim. The Executive shall permit the Company to control all proceedings related to the claim and, at its option, permit the Company to pursue or forgo any and all administrative appeals, proceedings, hearings, and conferences with the taxing authority in respect of such claim. If requested by the Company, the Executive agrees either to pay the tax claimed and sue for a refund or contest the claim in any permissible manner and to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction and in one or more appellate courts as the Company shall determine; provided, however, that, if the Company directs the Executive to pay such claim and pursue a refund, the Company shall advance the amount of such payment to the Executive on an after-tax and interest-free basis (the “Advance”). The Company’s control of the contest related to the claim shall be limited to the issues related to the Payments and the Executive shall be entitled to settle or contest, as the case may be, any other issues raised by the Internal Revenue Service or other taxing authority. The Advance or other payments and the reimbursement of any related costs, expenses or taxes payable under this Section 4(c) and/or Section 4(e) shall be made on or before the end of the Executive’s taxable year following the taxable year in which any additional taxes are payable by the Executive or if no additional taxes are payable the Executive’s taxable year following the taxable year in which the audit or litigation is closed. Notwithstanding the above, to the extent required to avoid the penalty taxes and interest payable under section 409A of the Code, if the Executive is a “specified person” within the meaning of that Code section, the Advance shall be delayed until the date that is six months following the Separation from Service. |
(d) | Repayments. If, after receipt by the Executive of an Advance, the Executive becomes entitled to a refund with respect to the claim to which such Advance relates, the Executive shall pay the Company the amount of the refund (together with any interest paid or credited thereon after Taxes applicable thereto). If, after receipt by the Executive of an Advance, a determination is made that the Executive shall not be entitled to any refund with respect to the claim and the Company does not promptly notify the Executive of its intent to contest the denial of refund, then the amount of the Advance shall not be required to be repaid by the Executive. |
(e) | Further Assurances. The Company shall indemnify the Executive and hold the Executive harmless, on an after-tax basis, from any costs, expenses, penalties, fines, interest or other liabilities (“Losses”) incurred by the Executive with respect to the exercise by the Company of any of its rights under this Section 4, including, without limitation, any Losses related to the Company’s decision to contest a claim or any imputed income to the Executive resulting from any Advance or action taken on the Executive’s behalf by the Company hereunder. Subject to the last sentence of Section 4(c), the Company shall pay all legal fees and expenses incurred under this Section 4 and shall promptly reimburse the Executive for the reasonable expenses incurred by the Executive in connection with any actions taken by the Company or required to be taken by the Executive hereunder. The Company shall also pay all of the fees and expenses of the Accounting Firm, including, without limitation, the fees and expenses related to the opinion referred to in Section 4(b). |
5. | Payment of Severance Compensation. The severance compensation set forth in Section 3(a) will be payable in 36 equal monthly installments commencing on the first day of the month following the month in which the Separation from Service occurs. Notwithstanding the above, in the event that the Executive is a “specified employee” within the meaning of Code section 409A, the first six monthly installments shall be paid in a lump sum on the first day of the month following or coincident with the date that is six months following the Separation from Service and all remaining monthly installments shall be paid monthly. |
6. | Legal Fees. The Company will pay all legal fees and expenses which the Executive may incur as a result of the Company’s contesting the validity or enforceability of this Agreement. |
7. | Payments Final. In the event of a termination of the Executive’s employment under the circumstances described in this Agreement, the arrangements provided for by this Agreement, and any other agreement between the Company and the Executive in effect at that time and by any other applicable plan of the Company in which the Executive then participates, will constitute the entire obligation of the Company to the Executive, and performance of that obligation will constitute full settlement of any claim that the Executive might otherwise assert against the Company on account of such termination. The Company’s obligation to pay the Executive under this Agreement will be absolute and unconditional and will not be affected by any circumstance, including without limitation, any set-off, counterclaim, defense or other rights the Company may have against the Executive or anyone else as long as the Executive is not in beach of the Executive’s obligations under this Agreement. |
8. | Non-Competition. |
(a) | During the one-year period following the Executive’s termination of employment covered by this Agreement, the Executive will not, and will not permit any of the Executive's Affiliates, or any other Person, directly or indirectly, to: |
(i) | engage in competition with, or acquire a direct or indirect interest or an option to acquire such an interest in any Person engaged in competition with, the Company's Business in the United States (other than an interest of not more than 5 percent of the outstanding stock of any publicly traded company); |
(ii) | serve as a director, officer, employee or consultant of, or furnish information to, or otherwise facilitate the efforts of, any Person engaged in competition with the Company's Business in the United States; |
(b) | solicit, employ, interfere with or attempt to entice away from the Company any employee who has been employed by the Company or a Subsidiary in an executive or supervisory capacity in connection with the conduct of the Company's Business within one year prior to such solicitation, employment, interference or enticement; or |
(c) | approach, solicit or deal with in competition with the Company or any Subsidiary any Person which at any time during the 12 months immediately preceding the Termination Date: |
(i) | was a customer, client, supplier, agent or distributor of the Company or any Subsidiary; |
(ii) | was a customer, client, supplier, agent or distributor of the Company or any Subsidiary with whom employees reporting to or under the direct control of the Executive had personal contact on behalf of the Company or any Subsidiary; or |
(iii) | was a Person with whom the Executive had regular, substantial or a series of business dealings on behalf of the Company or any Subsidiary (whether or not a customer, client, supplier, agent or distributor of the Company or any Subsidiary). |
(d) | The "Company's Business" means: (i) the manufacture and sale of stoppers, closures, containers, medical-device components and assemblies made from elastomers, metal and plastic for the health-care and consumer-products industries, and (ii) any other business conducted by the Company or any of its Subsidiaries or Affiliates during the term of this Agreement and in which the Executive has have been actively involved. |
9. | Confidentiality and Enforcement. Executive’s obligations under any Confidentiality and Non-Disclosure Agreements with the Company and the non-compete agreement described in Section 8 (collectively, the “Material Ancillary Agreements”) are hereby affirmed. A breach of any Material Ancillary Agreement is a breach of this Agreement and all Payments and obligations of the Company under this Agreement shall cease in the event of the breach of those Material Ancillary Agreements. The Executive acknowledges that a breach of the covenants contained in the Material Ancillary Agreements and incorporated by reference into this Agreement will cause the Company immediate and irreparable harm for which the Company’s remedies at law (such as money damages) will be inadequate. The Company shall have the right, in addition to any other rights it may have, to obtain an injunction to restrain any breach or threatened breach of such agreements. The Company may contact any Person with or for whom the Executive works after the Executive’s employment by the Company ends and may send that Person a copy of those agreements and/or this Agreement. In consideration of the benefit of having the protection afforded by this Agreement, the Executive agrees that the provisions of the Material Ancillary Agreements apply to the Executive, and the Executive will be bound by them, whether or not a Change in Control occurs or the Executive actually receives the benefits specified in Section 3. |
10. | Duration of Agreement. This Agreement commences on the Effective Date and will continue until terminated as provided in this Section. This Agreement may be terminated only under the following circumstances: |
(i) | At any time by the mutual written consent of the Executive and the Company; and |
(ii) | By the Company at the end of each successive two-year period commencing on the Effective Date by giving the Executive written notice at least one year in advance of such termination, except that such termination and written notice will not be effective unless the Executive will be employed by the Company on the Separation from Service. |
11. | Notices. Each party giving or making notice, request, demand or other communication (each, a “Notice”) under this Agreement shall give the Notice in writing and use one of the following methods of delivery: personal delivery, registered or certified mail with return receipt requested, nationally recognized overnight courier, fax or e-mail. Such Notice shall be addressed to the last address provided by the party receiving Notice. Notices are not effective unless compliant with this Section and provided within the timeframes required in this Agreement. |
12. | Integration. This Agreement together with the Material Ancillary Agreements constitutes the entire agreement and understanding between the Company and the Executive with respect to the subject matter hereof and merges and supersedes all prior discussions, agreements (written and verbal) and understandings between the Company and the Executive with respect to such matters. |
13. | Miscellaneous. |
(a) | This Agreement will be binding upon and inure to the benefit of the Executive, the Executive’s personal representatives and heirs and the Company and any successor of the Company, but neither this Agreement nor any rights arising hereunder may be assigned or pledged by the Executive. |
(b) | Should any provision of this Agreement be adjudged to any extent invalid by any competent tribunal, that provision will be deemed modified to the extent necessary to make it enforceable. The invalidity or unenforceability of any provision of this Agreement (or the Material Ancillary Agreements) shall in no way affect the validity or enforceability of any other provision hereof. |
(c) | This Agreement will be governed and construed in accordance with the laws of the Commonwealth of Pennsylvania. |
(d) | This Agreement may be executed in one or more counterparts, which together shall constitute a single agreement. |
1. | Termination of Employment During First Two Years of Employment. Subject to Section 3, you will be entitled to the benefits specified in Section 2 if on or before the second anniversary of your Start Date as defined in the Offer Letter, (i) your employment is terminated by the Company, other than for Cause (as such term is defined in the Sign-On Bonus Repayment Agreement which is Exhibit I to the Offer Letter (the “Repayment Agreement”)), or (ii) you terminate employment for Good Reason (as defined in the Repayment Agreement). You will not be entitled to the benefits specified in Section 2 if your employment terminates for any other reason, including, without limitation, your voluntary resignation, death, or disability, or if your employment terminates for any reason after the second anniversary of your Start Date. |
2. | Benefits Payable Upon Certain Terminations of Employment. Upon termination of employment as set forth in Section 1 and subject to Section 3, you shall be entitled to a lump-sum cash severance amount of $450,000 payable on the first normal payroll date following five business days after your covered termination of employment. |
3. | Release. You shall be entitled to the amounts, payments and benefits set forth in Section 2 only following the execution and effectiveness (without revocation) of a waiver and release of all claims related to your employment or termination thereof (other than claims under this Severance Agreement) in the form and manner presented by the Company. |
4. | Non-Disparagement. You understand and agree that as a condition for payment to you of the amounts and benefits provided under this Severance Agreement, you shall not make any false, disparaging or derogatory statements to any third party, including, without limitation, any media outlet, industry group, financial institution or current or former employee, consultant, client or customer of the Company regarding the Company, the Company’s employees or consultants, or the Company’s business affairs and financial condition. You agree further that you will not at any time speak or act in any manner that is intended to, or does in fact, damage the goodwill or the business of the Company, or the business or personal reputations of any of the Company’s employees. |
5. | Cooperation. You agree to cooperate with the Company with respect to all matters arising during or related to your employment about which you have personal knowledge because of your employment with the Company, including but not limited to all matters (formal or informal) in connection with any government investigation, internal Company investigation, litigation (potential or ongoing), administrative, regulatory, or other proceeding which currently exists, or which may have arisen before or arise following the signing of this Severance Agreement. Such cooperation will include, but not be limited to, your willingness to be interviewed by representatives of the Company, and to participate in such proceedings by deposition or testimony. You understand that the Company agrees to reimburse you for your reasonable out-of-pocket expenses (not including attorney's fees, legal costs or your lost time or opportunity) incurred in connection with such cooperation. |
6. | Confidentiality; Return of Property. |
a) | You confirm your obligations under your Confidentiality and Non-Disclosure Agreement(s) with the Company in effect from time-to-time, as amended. You further understand and agree that as a term and condition of receiving the benefits provided under this Severance Agreement, you agree to maintain as confidential, the terms and contents of this Severance Agreement except (a) as needed to obtain legal counsel, financial, or tax advice; (b) to the extent required by federal, state or local law or by order of court; or, (c) as otherwise agreed to in writing by an officer of the Company. |
b) | You agree within two business days following termination to return to the Company all Company- |
7. | Payments Final. In the event of a termination of your employment under the circumstances described in this Severance Agreement, the arrangements provided for by this Severance Agreement, or any other agreement between the Company and you in effect at that time and by any other applicable plan of the Company in which you then participate shall constitute the entire obligation of the Company to you, and performance of that obligation shall constitute the settlement of any claim that you might otherwise assert against the Company on account of such termination. |
8. | Duration of Agreement. This Severance Agreement may not be terminated by either party, except that this Severance Agreement may be terminated at any time by the mutual written consent of you and the Company. |
9. | Enforcement. You acknowledge that a breach of this Severance Agreement will cause the Company immediate and irreparable harm for which the Company’s remedies at law (such as money damages) will be inadequate. The Company shall have the right, in addition to any other rights it may have, to obtain an injunction to restrain any breach or threatened breach of this Severance Agreement. Should any provision of this Severance Agreement be adjudged to any extent invalid by any competent tribunal, that provision will be deemed modified to the extent necessary to make it enforceable. The Company may contact any person with or for whom you work after your employment by the Company ends and may send that person a copy of this Severance Agreement. |
10. | Miscellaneous. |
a) | Neither this Severance Agreement nor any of the rights arising hereunder may be assigned or pledged by you, however, this Severance Agreement will inure to the benefit of the successors and assigns of the Company. |
c) | This Severance Agreement shall in no way bind you or the Company to a specific term of employment. |
a) | The invalidity or unenforceability in any respect of any provision of this Severance Agreement shall not affect the validity or enforceability of such provision in any other respect or the validity or enforceability of any other provision. |
b) | The headings or titles of Sections appearing in this Severance Agreement are provided for convenience and are not to be used in construing this Severance Agreement. |
c) | This Severance Agreement shall be governed and construed in accordance with the laws of the Commonwealth of Pennsylvania. |
d) | This Severance Agreement, and the documents referenced herein, constitute the entire agreement and understanding between the Company and you relating to the subject matter hereof, and supersedes all prior agreements, which shall be deemed to be terminated upon the date of this Severance Agreement, arrangements and understandings, written or oral, between the Company and you. |
Natsyn® [***] synthetic polyisoprene rubber | [***] /lb |
Natsyn® [***] synthetic polyisoprene rubber | [***] /lb |
Natsyn® [***] synthetic polyisoprene rubber | [***] /lb |
Natsyn® [***] synthetic polyisoprene rubber | [***] /lb |
Plioflex® [***] emulsion styrene-butadiene rubber | [***] /lb |
Price of [***] per [***] | Surcharge per Product Pound |
[***] to [***] | [***] |
[***] to [***] | [***] |
[***] to [***] | [***] |
[***] to [***] | [***] |
Price of [***] | Surcharge per Product Pound |
[***] to [***] | [***] |
[***] to [***] | [***] |
[***] to [***] | [***] |
[***] to [***] | [***] |
(1) | This Amendment shall be effective as of December 31, 2015. |
(2) | This Amendment contains the entire agreement of the parties with respect to changes to the Agreement, and there are no oral understandings, representations or warranties affecting it. |
(3) | Except as expressly modified by this Amendment, the terms and conditions of the Agreement shall remain unchanged. The Agreement, as modified by this Amendment, remains in full force and effect. |
1. | I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
1. | I have reviewed this quarterly report on Form 10-Q of West Pharmaceutical Services, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Document and Entity Information |
9 Months Ended |
---|---|
Sep. 30, 2016
shares
| |
Document and Entity Information [Abstract] | |
Entity Registrant Name | WEST PHARMACEUTICAL SERVICES INC |
Entity Central Index Key | 0000105770 |
Current Fiscal Year End Date | --12-31 |
Entity Well-known Seasoned Issuer | Yes |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Filer Category | Large Accelerated Filer |
Entity Common Stock, Shares Outstanding | 73,184,116 |
Document Fiscal Year Focus | 2016 |
Document Fiscal Period Focus | Q3 |
Document Type | 10-Q |
Amendment Flag | false |
Document Period End Date | Sep. 30, 2016 |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
Income Statement [Abstract] | ||||
Net sales | $ 376.7 | $ 344.5 | $ 1,126.8 | $ 1,040.1 |
Cost of goods and services sold | 255.6 | 236.2 | 749.1 | 703.9 |
Gross profit | 121.1 | 108.3 | 377.7 | 336.2 |
Research and development | 9.0 | 8.5 | 27.2 | 24.1 |
Selling, general and administrative expenses | 58.3 | 54.6 | 178.9 | 170.6 |
Other expense (Note 12) | 2.5 | 48.7 | 29.1 | 58.1 |
Operating profit (loss) | 51.3 | (3.5) | 142.5 | 83.4 |
Interest expense | 2.2 | 3.7 | 6.7 | 11.2 |
Interest income | 0.2 | 0.5 | 0.8 | 1.3 |
Income (loss) before income taxes | 49.3 | (6.7) | 136.6 | 73.5 |
Income tax expense (benefit) | 14.4 | (6.6) | 38.3 | 15.1 |
Equity in net income of affiliated companies | 2.7 | 1.6 | 6.2 | 3.8 |
Net income | $ 37.6 | $ 1.5 | $ 104.5 | $ 62.2 |
Net income per share: | ||||
Basic (in dollars per share) | $ 0.51 | $ 0.02 | $ 1.43 | $ 0.86 |
Diluted (in dollars per share) | $ 0.50 | $ 0.02 | $ 1.40 | $ 0.85 |
Weighted average shares outstanding: | ||||
Basic (in shares) | 73.3 | 72.2 | 73.0 | 71.9 |
Diluted (in shares) | 75.0 | 73.9 | 74.7 | 73.6 |
Dividends declared per share | $ 0.13 | $ 0.12 | $ 0.37 | $ 0.34 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 37.6 | $ 1.5 | $ 104.5 | $ 62.2 |
Other comprehensive income (loss), net of tax: | ||||
Foreign currency translation adjustments | 5.9 | (13.5) | 15.9 | (58.0) |
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.3, $11.4, $0.9 and $12.3, respectively | 0.6 | 19.7 | 2.2 | 21.3 |
Net gains (losses) on derivatives, net of tax of $(0.1), $(0.1), $0.4 and $0.7, respectively | 0.0 | (0.4) | 0.7 | 1.5 |
Other comprehensive income (loss), net of tax | 6.5 | 5.8 | 18.8 | (35.2) |
Comprehensive income | $ 44.1 | $ 7.3 | $ 123.3 | $ 27.0 |
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
Statement of Comprehensive Income [Abstract] | ||||
Defined benefit pension and other postretirement plan adjustments, tax | $ 0.3 | $ 11.4 | $ 0.9 | $ 12.3 |
Net (losses) gains on derivatives, tax | $ (0.1) | $ (0.1) | $ 0.4 | $ 0.7 |
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares shares in Millions |
Sep. 30, 2016 |
Dec. 31, 2015 |
---|---|---|
Balance Sheet Related Disclosures [Abstract] | ||
Preferred Stock, Shares Authorized | 3.0 | 3.0 |
Preferred Stock, Shares Issued | 0.0 | 0.0 |
Preferred Stock, Shares Outstanding | 0.0 | 0.0 |
Common Stock, Par or Stated Value Per Share | $ 0.25 | $ 0.25 |
Common Stock, Shares Authorized | 100.0 | 100.0 |
Common Stock, Shares, Issued | 73.5 | 72.4 |
Common Stock, Shares, Outstanding | 73.2 | 72.3 |
Treasury Stock, Shares | 0.3 | 0.1 |
CONDENSED CONSOLIDATED STATEMENT OF EQUITY (UNAUDITED) - 9 months ended Sep. 30, 2016 - USD ($) shares in Millions, $ in Millions |
Total |
Common Stock [Member] |
Capital in Excess of Par Value [Member] |
Treasury Stock [Member] |
Retained Earnings [Member] |
Accumulated Other Comprehensive Loss [Member] |
---|---|---|---|---|---|---|
Balance at Dec. 31, 2015 | $ 1,023.9 | $ 18.1 | $ 207.8 | $ (4.0) | $ 964.6 | $ (162.6) |
Balance (in shares) at Dec. 31, 2015 | 72.4 | |||||
Increase (Decrease) in Equity [Roll Forward] | ||||||
Net income | 104.5 | 104.5 | ||||
Stock-based compensation | 13.0 | 12.7 | 0.3 | |||
Shares issued under stock plans (shares) | 1.2 | |||||
Shares issued under stock plans | 25.9 | $ 0.3 | 16.9 | 8.7 | ||
Shares repurchased under share repurchase program | (26.8) | (26.8) | ||||
Shares repurchased for employee tax withholdings (shares) | (0.1) | |||||
Shares repurchased for employee tax withholdings | (3.7) | (3.7) | ||||
Excess tax benefit from employee stock plans | 13.9 | 13.9 | ||||
Dividends declared | (27.2) | (27.2) | ||||
Other comprehensive income, net of tax | 18.8 | 18.8 | ||||
Balance at Sep. 30, 2016 | $ 1,142.3 | $ 18.4 | $ 247.6 | $ (21.8) | $ 1,041.9 | $ (143.8) |
Balance (in shares) at Sep. 30, 2016 | 73.5 |
Summary of Significant Accounting Policies |
9 Months Ended |
---|---|
Sep. 30, 2016 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2016 should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. (which may be referred to as “West”, “the Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year. Segment Reporting: Beginning in 2016, we changed our organization and reporting structure for our next phase of growth and development, which resulted in a change to Proprietary Products and Contract-Manufactured Products as our reportable segments. Segment results presented in the accompanying condensed consolidated financial statements and related notes have been retroactively adjusted to reflect the impact of this change. Please refer to Note 15, Segment Information, for additional details. |
New Accounting Standards |
9 Months Ended |
---|---|
Sep. 30, 2016 | |
New Accounting Pronouncements and Changes in Accounting Principles [Abstract] | |
New Accounting Standards | New Accounting Standards Recently Adopted Standards In September 2015, the Financial Accounting Standards Board (“FASB”) issued guidance that simplifies the accounting for measurement-period adjustments in business combinations, by eliminating the requirement to account for those adjustments retrospectively. Instead, the acquirer will be required to recognize measurement-period adjustments in the reporting period in which the amounts are determined. We adopted this guidance as of January 1, 2016, on a prospective basis. The adoption did not have a material impact on our financial statements. In April 2015, the FASB issued guidance on the accounting for fees paid by a customer in a cloud computing arrangement. We adopted this guidance as of January 1, 2016, on a prospective basis. The adoption did not have a material impact on our financial statements. In February 2015, the FASB issued amended guidance that changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. We adopted this guidance as of January 1, 2016, on a prospective basis. The adoption did not have a material impact on our financial statements. In January 2015, the FASB issued guidance which removes the concept of extraordinary items from U.S. GAAP. This guidance eliminates the requirement for companies to spend time assessing whether items meet the criteria of being both unusual and infrequent. We adopted this guidance as of January 1, 2016. The adoption did not have a material impact on our financial statements. In June 2014, the FASB issued guidance that clarifies the accounting for share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. In this case, the performance target would be required to be treated as a performance condition, and should not be reflected in estimating the grant-date fair value of the award. The guidance also addresses when to recognize the related compensation cost. We adopted this guidance as of January 1, 2016. The adoption did not have a material impact on our financial statements. Standards Issued Not Yet Adopted In August 2016, the FASB issued guidance to reduce the diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. Management is currently evaluating the impact that this guidance will have on our financial statements. In March 2016, the FASB issued guidance that simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted. Management is currently evaluating the impact that this guidance will have on our financial statements. In March 2016, the FASB issued guidance that simplifies the transition to the equity method of accounting. This guidance eliminates the requirement to retroactively adopt the equity method of accounting when there is an increase in the level of ownership interest or degree of influence. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In February 2016, the FASB issued guidance on the accounting for leases. This guidance requires lessees to recognize lease assets and lease liabilities on the balance sheet and to expand disclosures about leasing arrangements, both qualitative and quantitative. In terms of transition, the guidance requires adoption based upon a modified retrospective approach. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Management is currently evaluating the impact that this guidance will have on our financial statements. In January 2016, the FASB issued guidance that addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In July 2015, the FASB issued guidance regarding the subsequent measurement of inventory. This guidance requires inventory measured using any method other than last-in, first-out or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value represents estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In August 2014, the FASB issued guidance which defines management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. This guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In May 2014, the FASB issued guidance on the accounting for revenue from contracts with customers that will supersede most existing revenue recognition guidance, including industry-specific guidance. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the guidance requires enhanced disclosures regarding the nature, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The FASB subsequently issued additional clarifying standards to address issues arising from implementation of the new revenue recognition standard. This guidance is effective for interim and annual reporting periods beginning on or after December 15, 2017. Early adoption is permitted as of one year prior to the current effective date. Entities can choose to apply the guidance using either a full retrospective approach or a modified retrospective approach. Management is continuing to evaluate the impact that this guidance will have on our financial statements. |
Net Income Per Share |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Income Per Share | Net Income Per Share The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
During the three months ended September 30, 2016 and 2015, there were 0.1 million and 0.8 million shares, respectively, not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.1 million and 0.6 million antidilutive shares outstanding during the nine months ended September 30, 2016 and 2015, respectively. In December 2015, we announced a share repurchase program authorizing the repurchase of up to 700,000 shares of the Company’s common stock from time to time on the open market or in privately-negotiated transactions as permitted under the Securities Exchange Act of 1934 Rule 10b-18. The number of shares to be repurchased and the timing of such transactions will depend on a variety of factors, including market conditions. The program commenced on January 1, 2016 and is expected to be completed by December 31, 2016. During the three months ended September 30, 2016, the Company purchased 117,310 shares of its common stock under this program at a cost of $9.6 million, or an average price of $81.46 per share. During the nine months ended September 30, 2016, the Company purchased 370,810 shares of its common stock under this program at a cost of $26.8 million, or an average price of $72.14 per share. |
Inventories |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories Inventories are valued at the lower of cost (on a first-in, first-out basis) or market. Inventory balances were as follows:
|
Affiliated Companies |
9 Months Ended |
---|---|
Sep. 30, 2016 | |
Equity Method Investments and Joint Ventures [Abstract] | |
Affiliated Companies | Affiliated Companies During the second quarter of 2016, we made an $8.4 million cost-method investment in an intradermal drug delivery company. At September 30, 2016 and December 31, 2015, the aggregate carrying amount of investments in equity-method affiliates was $68.0 million and $56.3 million, respectively, and the aggregate carrying amount of cost-method investments was $13.4 million and $5.0 million, respectively. Please refer to Note 5, Affiliated Companies, to the consolidated financial statements in our 2015 Annual Report for additional details. |
Debt |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt | Debt The following table summarizes our long-term debt obligations, net of current maturities and unamortized debt issuance costs. The interest rates shown in parentheses are as of December 31, 2015.
Please refer to Note 8, Debt, to the consolidated financial statements in our 2015 Annual Report for additional details regarding our debt agreements. At September 30, 2016, we had $28.5 million in outstanding borrowings under our $300.0 million multi-currency revolving credit facility, of which $4.9 million was denominated in Japanese Yen (“Yen”) and $23.6 million was denominated in Euro. The total amount outstanding under this facility at September 30, 2016 and December 31, 2015 was classified as long-term. These borrowings, together with outstanding letters of credit of $3.0 million, resulted in a borrowing capacity available under this facility of $268.5 million at September 30, 2016. Please refer to Note 7, Derivative Financial Instruments, for a discussion of the foreign currency hedges associated with this facility. In addition, at September 30, 2016, we had $35.4 million outstanding under our five-year term loan due January 2018, of which $2.5 million was classified as current. Please refer to Note 7, Derivative Financial Instruments, for a discussion of the interest-rate swap agreement associated with this loan. |
Derivative Financial Instruments |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Financial Instruments | Derivative Financial Instruments Our ongoing business operations expose us to various risks such as fluctuating interest rates, foreign exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments such as interest rate swaps, options and foreign exchange contracts for periods consistent with and for notional amounts equal to or less than the related underlying exposures. We do not purchase or hold any derivative financial instruments for speculation or trading purposes. All derivatives are recorded on the balance sheet at fair value. Interest Rate Risk At September 30, 2016, we had a $35.4 million forward-start interest rate swap outstanding that hedges the variability in cash flows due to changes in the applicable interest rate of our variable-rate five-year term loan. Under this swap, we receive variable interest rate payments based on one-month London Interbank Offered Rate (“LIBOR”) plus a margin in return for making monthly fixed interest payments at 5.41%. We designated this swap as a cash flow hedge. Foreign Exchange Rate Risk In 2015, we entered into a €20.0 million forward exchange contract, designated as a fair value hedge, to neutralize our exposure to fluctuating foreign exchange rates on a cross-currency intercompany loan. Changes in the fair value of this derivative are recognized within other expense and are offset by changes in the fair value of the underlying exposure being hedged. In addition, in 2015 and 2016, we entered into the following foreign currency hedge contracts that were designated as cash flow hedges of forecasted transactions denominated in foreign currencies. In 2015, we entered into a series of foreign currency contracts intended to hedge the currency risk associated with a portion of our forecasted U.S. dollar (“USD”)-denominated inventory purchases made by certain European subsidiaries. The remaining notional amount is €5.5 million ($6.1 million). We also entered into a series of foreign currency contracts in 2015 to hedge the currency risk associated with a portion of our forecasted Euro-denominated sales of finished goods by one of our USD functional-currency subsidiaries. The remaining notional amount is €4.5 million ($4.9 million). In 2016, we entered into a series of foreign currency contracts to hedge the currency risk associated with a portion of our forecasted Yen-denominated inventory purchases made by West in the U.S. The remaining notional amount is ¥355.1 million ($3.0 million). We also entered into a series of foreign currency contracts in 2016 to hedge the currency risk associated with a portion of our forecasted Yen-denominated inventory purchases made by certain European subsidiaries. The remaining notional amount is ¥180.0 million ($1.6 million). At September 30, 2016, a portion of our debt consisted of borrowings denominated in currencies other than USD. We have designated our €21.0 million ($23.6 million) Euro-denominated borrowings under our multi-currency revolving credit facility as a hedge of our net investment in certain European subsidiaries. A cumulative foreign currency translation gain of $0.3 million pre-tax ($0.2 million after tax) on this debt was recorded within accumulated other comprehensive loss as of September 30, 2016. We have also designated our ¥500.0 million ($4.9 million) Yen-denominated borrowings under our multi-currency revolving credit facility as a hedge of our net investment in Daikyo Seiko, Ltd. (“Daikyo”). At September 30, 2016, there was a cumulative foreign currency translation loss on this Yen-denominated debt of $0.8 million pre-tax ($0.5 million after tax), which was also included within accumulated other comprehensive loss. Commodity Price Risk Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception. In February 2016, we purchased a series of call options for a total of 71,900 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regard to a portion of our forecasted elastomer purchases through December 2016. With these contracts we may benefit from a decline in crude oil prices, as there is no downward exposure other than the $0.2 million premium that we paid to purchase the contracts. During the three and nine months ended September 30, 2016, the gain recorded in cost of goods and services sold related to these call options was $0.1 million. Effects of Derivative Instruments on Financial Position and Results of Operations The following tables summarize the effects of derivative instruments designated as hedges on other comprehensive income (“OCI”) and earnings, net of tax:
For the three and nine months ended September 30, 2016 and 2015, there was no material ineffectiveness related to our hedges. |
Fair Value Measurements |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:
The following tables present the assets and liabilities recorded at fair value on a recurring basis:
Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current assets and other current liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. Our interest rate swap, included within other long-term liabilities, is valued based on the terms of the contract and observable market inputs (i.e., LIBOR, Eurodollar synthetic forwards and swap spreads). Please refer to Note 7, Derivative Financial Instruments, for further discussion of our derivatives. Level 3 Fair Value Measurements The fair value of the contingent consideration liability related to our SmartDose® electronic patch injector system (“SmartDose contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. As development and commercialization of SmartDose progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the contingent consideration liability. The following table provides a summary of changes in our Level 3 fair value measurements:
Other Financial Instruments We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2016, the estimated fair value of long-term debt was $240.4 million compared to a carrying amount of $228.6 million. At December 31, 2015, the estimated fair value of long-term debt was $225.0 million and the carrying amount was $228.9 million. |
Stock-Based Compensation |
9 Months Ended |
---|---|
Sep. 30, 2016 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Stock-Based Compensation | Stock-Based Compensation On May 3, 2016, at our 2016 Annual Meeting of Shareholders, our shareholders approved the adoption of the West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”). All remaining shares available for issuance under the 2011 Omnibus Incentive Compensation Plan (the “2011 Plan”) were extinguished upon adoption of the 2016 Plan. Awards granted under previous plans remain outstanding until expiration or settlement. The 2016 Plan provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2016, there were 5,422,685 shares remaining in the 2016 Plan for future grants. During the nine months ended September 30, 2016, we granted 607,228 stock options at a weighted average exercise price of $63.75 per share based on the grant-date fair value of our stock to key employees under the 2011 and 2016 Plans. The weighted average grant date fair value of options granted was $12.35 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 1.43%; expected life of 5.9 years based on prior experience; stock volatility of 21.6% based on historical data; and a dividend yield of 1.0%. Stock option expense is recognized over the vesting period, net of forfeitures. During the nine months ended September 30, 2016, we granted 114,029 performance vesting share (“PVS”) awards at a weighted average grant-date fair value of $60.37 per share to key employees under the 2011 and 2016 Plans. Each PVS award entitles the holder to one share of our common stock if the annual growth rate of revenue and return on invested capital targets are achieved over a three-year performance period. Shares earned under PVS awards may vary from 0% to 200% of an employee’s targeted award. The fair value of PVS awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. Total stock-based compensation expense was $4.6 million and $14.1 million for the three and nine months ended September 30, 2016, respectively. For the three and nine months ended September 30, 2015, stock-based compensation expense was $3.6 million and $24.4 million, respectively. Included in the 2015 year-to-date amount was a $10.4 million charge related to executive retirements, which was recorded within other expense. Refer to Note 12, Other Expense, for further discussion of this charge. The remainder of 2015 stock-based compensation expense was recorded within selling, general and administrative expenses. |
Benefit Plans |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Benefit Plans | Benefit Plans The components of net periodic benefit cost for the three months ended September 30 were as follows ($ in millions):
The components of net periodic benefit cost for the nine months ended September 30 were as follows ($ in millions):
During the third quarter of 2015, we recorded a $49.0 million pension settlement charge, within other expense, in connection with our purchase of a group annuity contract from Metropolitan Life Insurance Company (“MetLife”) to settle $139.4 million of our $313.6 million outstanding pension benefit obligation under our U.S. qualified pension plan. MetLife assumed the obligation to pay future pension benefits and provide administrative services beginning November 1, 2015 for approximately 1,750 retirees and surviving beneficiaries who retired prior to January 1, 2015 and were receiving payments from this plan. The purchase was funded directly by plan assets. In addition, we made contributions to the U.S. qualified pension plan in the amount of $1.3 million in September 2015 and $13.7 million in October 2015, in order to maintain the plan's funded status as of the transaction date. |
Accumulated Other Comprehensive Loss |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accumulated Other Comprehensive Loss | Accumulated Other Comprehensive Loss The following table presents the changes in the components of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2016:
A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):
(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 10, Benefit Plans, for additional details. |
Other Expense |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Expense | Other Expense Other expense consists of:
Restructuring and Related Charges On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. We expect to incur total restructuring and related charges of $25.0 million to $28.0 million under this plan, which consists of approximately $8.0 million in severance charges for personnel reductions and $17.0 million to $20.0 million in non-cash asset write-downs. During the three months ended September 30, 2016, we recorded $2.3 million in restructuring and related charges, consisting of $1.4 million for severance charges and $0.9 million for a non-cash asset write-down associated with the discontinued use of certain equipment. During the nine months ended September 30, 2016, we incurred $23.7 million in restructuring and related charges, consisting of $7.8 million for severance charges, $10.0 million for a non-cash asset write-down associated with the discontinued use of a trademark, and $5.9 million for non-cash asset write-downs associated with the discontinued use of a patent and certain equipment. The balance of the charges related to this plan will be recognized as incurred during the remainder of 2016 and in 2017. The following table presents activity related to our restructuring obligations:
Other Items During the third quarter of 2015, we recorded a $49.0 million pension settlement charge in connection with our purchase of a group annuity contract from MetLife. Please refer to Note 10, Benefit Plans, for additional details regarding this purchase. During the nine months ended September 30, 2015, we recorded a $10.9 million charge for executive retirement and related costs, including $2.4 million for a long-term incentive plan award for our previous Chief Executive Officer (“CEO”), $8.0 million for the revaluation of modified outstanding awards to provide for continued vesting for our previous CEO and Senior Vice President of Human Resources in conjunction with their retirement, and $0.5 million for other costs, including relocation and legal fees. On February 17, 2016, the Venezuelan government announced a devaluation of the Bolivar, from the previously-prevailing official exchange rate of 6.3 Bolivars to USD to 10.0 Bolivars to USD, and streamlined the previous three-tiered currency exchange mechanism into a dual currency exchange mechanism. As a result, during the nine months ended September 30, 2016, we recorded a $2.7 million charge. After the remeasurement, as of September 30, 2016, we had $3.9 million in net monetary assets denominated in Venezuelan Bolivars, including $2.9 million in cash and cash equivalents, and $1.4 million in non-monetary assets. If there are further devaluations of the Bolivar or other changes in the currency exchange mechanisms in Venezuela in the future, a pre-tax charge of up to $6.0 million could be required. We will continue to actively monitor the political and economic developments in Venezuela. In addition, during the three and nine months ended September 30, 2016, we recognized development income of $0.4 million and $1.2 million, respectively, within our Proprietary Products segment, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of SmartDose within a specific therapeutic area. During the three and nine months ended September 30, 2015, we recognized development income of $0.3 million and $1.1 million, respectively. As of September 30, 2016, there was $14.8 million of unearned income related to this payment, of which $1.5 million was included in other current liabilities and $13.3 million was included in other long-term liabilities. The unearned income is being recognized as development income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer. Contingent consideration costs represent changes in the fair value of the SmartDose contingent consideration. Please refer to Note 8, Fair Value Measurements, for additional details. Other items consist of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, and miscellaneous income and charges. |
Income Taxes |
9 Months Ended |
---|---|
Sep. 30, 2016 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items. The provision for income taxes was $14.4 million and $38.3 million for the three and nine months ended September 30, 2016, respectively, and the effective tax rate was 29.3% and 28.1%, respectively. During the three and nine months ended September 30, 2016, we recorded a tax benefit of $0.7 million and $8.1 million, respectively, in connection with restructuring and related charges discussed in Note 12, Other Expense, as well as a discrete tax charge of $0.3 million resulting from the impact of a change in the enacted tax rate in the United Kingdom on our previously-recorded deferred tax asset balances. During the three months ended September 30, 2015, we recorded a tax benefit of $6.6 million, which included a tax benefit of $17.9 million in connection with the $49.0 million pension settlement charge discussed in Note 10, Benefit Plans. The provision for income taxes was $15.1 million for the nine months ended September 30, 2015. In addition to the tax benefit on the pension settlement charge, our 2015 year-to-date results included a tax benefit $4.0 million in connection with a $10.9 million charge for executive retirement and related costs discussed in Note 12, Other Expense. |
Commitments and Contingencies |
9 Months Ended |
---|---|
Sep. 30, 2016 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity. There have been no significant changes to the commitments and contingencies included in our 2015 Annual Report. |
Segment Information |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information | Segment Information In 2015, our business operations consisted of two reportable segments, the Pharmaceutical Packaging Systems segment (“Packaging Systems”) and the Pharmaceutical Delivery Systems segment (“Delivery Systems”). Beginning in 2016, we changed our organization and reporting structure for our next phase of growth and development, which resulted in a change to Proprietary Products and Contract-Manufactured Products as our reportable segments. The Proprietary Products reportable segment, which is a combination of the previous Packaging Systems segment and the proprietary products portion of the previous Delivery Systems segment, develops commercial, operational, and innovation strategies across our global network, with specific emphasis on product offerings to biologic, generic, and pharmaceutical customers. The Contract-Manufactured Products reportable segment, which consists of the contract manufacturing portion of the previous Delivery Systems segment, serves as a fully integrated business focused on the design, manufacture, and automated assembly of complex assemblies for pharmaceutical, diagnostic, and medical device customers. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that management considers not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The following table presents information about our reportable segments, reconciled to consolidated totals:
The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments. Other unallocated items, during the three and nine months ended September 30, 2016, consist of restructuring and related charges of $2.3 million and $23.7 million, respectively. In addition, during the nine months ended September 30, 2016, we recorded a charge of $2.7 million related to the devaluation of the Venezuelan Bolivar. During the three and nine months ended September 30, 2015, we recorded a $49.0 million pension settlement charge in connection with our purchase of a group annuity contract from MetLife. In addition, the nine months ended September 30, 2015 includes a $10.9 million charge for executive retirement and related costs. Please refer to Note 12, Other Expense, for additional details of these items. |
Summary of Significant Accounting Policies (Policies) |
9 Months Ended |
---|---|
Sep. 30, 2016 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation: The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2016 should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. (which may be referred to as “West”, “the Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Annual Report”). The results of operations for any interim period are not necessarily indicative of results for the full year. |
Segment Reporting | Segment Reporting: Beginning in 2016, we changed our organization and reporting structure for our next phase of growth and development, which resulted in a change to Proprietary Products and Contract-Manufactured Products as our reportable segments. Segment results presented in the accompanying condensed consolidated financial statements and related notes have been retroactively adjusted to reflect the impact of this change. Please refer to Note 15, Segment Information, for additional details. |
New Accounting Standards | Recently Adopted Standards In September 2015, the Financial Accounting Standards Board (“FASB”) issued guidance that simplifies the accounting for measurement-period adjustments in business combinations, by eliminating the requirement to account for those adjustments retrospectively. Instead, the acquirer will be required to recognize measurement-period adjustments in the reporting period in which the amounts are determined. We adopted this guidance as of January 1, 2016, on a prospective basis. The adoption did not have a material impact on our financial statements. In April 2015, the FASB issued guidance on the accounting for fees paid by a customer in a cloud computing arrangement. We adopted this guidance as of January 1, 2016, on a prospective basis. The adoption did not have a material impact on our financial statements. In February 2015, the FASB issued amended guidance that changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. We adopted this guidance as of January 1, 2016, on a prospective basis. The adoption did not have a material impact on our financial statements. In January 2015, the FASB issued guidance which removes the concept of extraordinary items from U.S. GAAP. This guidance eliminates the requirement for companies to spend time assessing whether items meet the criteria of being both unusual and infrequent. We adopted this guidance as of January 1, 2016. The adoption did not have a material impact on our financial statements. In June 2014, the FASB issued guidance that clarifies the accounting for share-based payments in which the terms of the award provide that a performance target that affects vesting could be achieved after the requisite service period. In this case, the performance target would be required to be treated as a performance condition, and should not be reflected in estimating the grant-date fair value of the award. The guidance also addresses when to recognize the related compensation cost. We adopted this guidance as of January 1, 2016. The adoption did not have a material impact on our financial statements. Standards Issued Not Yet Adopted In August 2016, the FASB issued guidance to reduce the diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. Management is currently evaluating the impact that this guidance will have on our financial statements. In March 2016, the FASB issued guidance that simplifies several aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted. Management is currently evaluating the impact that this guidance will have on our financial statements. In March 2016, the FASB issued guidance that simplifies the transition to the equity method of accounting. This guidance eliminates the requirement to retroactively adopt the equity method of accounting when there is an increase in the level of ownership interest or degree of influence. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In February 2016, the FASB issued guidance on the accounting for leases. This guidance requires lessees to recognize lease assets and lease liabilities on the balance sheet and to expand disclosures about leasing arrangements, both qualitative and quantitative. In terms of transition, the guidance requires adoption based upon a modified retrospective approach. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Management is currently evaluating the impact that this guidance will have on our financial statements. In January 2016, the FASB issued guidance that addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In July 2015, the FASB issued guidance regarding the subsequent measurement of inventory. This guidance requires inventory measured using any method other than last-in, first-out or the retail inventory method to be measured at the lower of cost and net realizable value. Net realizable value represents estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In August 2014, the FASB issued guidance which defines management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. This guidance is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. Management believes that the adoption of this guidance will not have a material impact on our financial statements. In May 2014, the FASB issued guidance on the accounting for revenue from contracts with customers that will supersede most existing revenue recognition guidance, including industry-specific guidance. The core principle requires an entity to recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the guidance requires enhanced disclosures regarding the nature, timing and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The FASB subsequently issued additional clarifying standards to address issues arising from implementation of the new revenue recognition standard. This guidance is effective for interim and annual reporting periods beginning on or after December 15, 2017. Early adoption is permitted as of one year prior to the current effective date. Entities can choose to apply the guidance using either a full retrospective approach or a modified retrospective approach. Management is continuing to evaluate the impact that this guidance will have on our financial statements. |
Net Income Per Share (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Basic to Diluted Net Income Per Share | The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share:
|
Inventories (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventory Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories | Inventories are valued at the lower of cost (on a first-in, first-out basis) or market. Inventory balances were as follows:
|
Debt (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt Obligations, Net of Current Maturities | The following table summarizes our long-term debt obligations, net of current maturities and unamortized debt issuance costs. The interest rates shown in parentheses are as of December 31, 2015.
|
Derivative Financial Instruments (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings | The following tables summarize the effects of derivative instruments designated as hedges on other comprehensive income (“OCI”) and earnings, net of tax:
|
Fair Value Measurements (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Assets and Liabilities Measured at Fair Value | The following tables present the assets and liabilities recorded at fair value on a recurring basis:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Changes in Level 3 Fair Value Measurements | The following table provides a summary of changes in our Level 3 fair value measurements:
|
Benefit Plans (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Components of Net Periodic Benefit Cost | The components of net periodic benefit cost for the three months ended September 30 were as follows ($ in millions):
The components of net periodic benefit cost for the nine months ended September 30 were as follows ($ in millions):
|
Accumulated Other Comprehensive Loss (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Components of Accumulated Other Comprehensive Loss | The following table presents the changes in the components of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2016:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassification out of Accumulated Other Comprehensive Loss | A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table ($ in millions):
(a) These components are included in the computation of net periodic benefit cost. Please refer to Note 10, Benefit Plans, for additional details. |
Other Expense (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Income and Expenses [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Other Expense | Other expense consists of:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Restructuring Reserve | The following table presents activity related to our restructuring obligations:
|
Segment Information (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Information | The following table presents information about our reportable segments, reconciled to consolidated totals:
|
Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
Earnings Per Share [Abstract] | ||||
Net income | $ 37.6 | $ 1.5 | $ 104.5 | $ 62.2 |
Weighted average common shares outstanding (in shares) | 73,300,000 | 72,200,000 | 73,000,000 | 71,900,000 |
Dilutive effect of stock options, stock appreciation rights and performance share awards, based on the treasury stock method (in shares) | 1,700,000 | 1,700,000 | 1,700,000 | 1,700,000 |
Weighted average shares assuming dilution (in shares) | 75,000,000 | 73,900,000 | 74,700,000 | 73,600,000 |
Antidilutive options excluded from computation of diluted net income per share (in shares) | 100,000 | 800,000 | 100,000 | 600,000 |
Stock repurchase program, shares authorized | 700,000 | 700,000 | ||
Stock repurchase program, shares purchased | 117,310 | 370,810 | ||
Stock repurchase program, cost of shares purchased | $ 9.6 | $ 26.8 | ||
Stock repurchase program, average price per share | $ 81.46 | $ 72.14 |
Inventories (Details) - USD ($) $ in Millions |
Sep. 30, 2016 |
Dec. 31, 2015 |
---|---|---|
Inventory Disclosure [Abstract] | ||
Raw materials | $ 82.5 | $ 74.4 |
Work in process | 32.2 | 30.1 |
Finished goods | 86.4 | 76.6 |
Total inventories | $ 201.1 | $ 181.1 |
Affiliated Companies (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2016 |
Sep. 30, 2016 |
Sep. 30, 2015 |
Dec. 31, 2015 |
|
Equity Method Investments and Joint Ventures [Abstract] | ||||
Purchase of cost-method investment | $ 8.4 | $ 8.4 | $ 0.0 | |
Carrying amount, equity-method investments | 68.0 | $ 56.3 | ||
Carrying amount, cost-method investments | $ 13.4 | $ 5.0 |
Derivative Financial Instruments (Details) - ERROR in label resolution. € in Millions, ¥ in Millions, $ in Millions |
3 Months Ended | 9 Months Ended | ||||
---|---|---|---|---|---|---|
Sep. 30, 2016
USD ($)
|
Sep. 30, 2016
EUR (€)
MBbls
|
Sep. 30, 2016
JPY (¥)
|
Sep. 30, 2016
USD ($)
|
Sep. 30, 2016
JPY (¥)
MBbls
|
Sep. 30, 2016
USD ($)
MBbls
|
|
Derivative [Line Items] | ||||||
Notional amount | $ 35.4 | |||||
Maximum term (in years) | 5 years | 5 years | 5 years | |||
Derivative, underlying basis | one-month London Interbank Offered Rate (“LIBOR”) | one-month London Interbank Offered Rate (“LIBOR”) | one-month London Interbank Offered Rate (“LIBOR”) | |||
Fixed interest rate | 5.41% | 5.41% | 5.41% | |||
Notional amount | € 5.5 | $ 6.1 | ||||
Notional amount | 4.5 | 4.9 | ||||
Notional amount | ¥ 355.1 | 3.0 | ||||
Notional amount | ¥ 180.0 | 1.6 | ||||
Notional amount, nonderivative instruments | € 21.0 | $ 23.6 | ||||
Cumulative foreign currency translation gain | 0.3 | |||||
Cumulative foreign currency translation gain, net of tax | 0.2 | |||||
Notional amount, nonderivative instruments | ¥ 500.0 | 4.9 | ||||
Cumulative foreign currency translation gain | 0.8 | |||||
Cumulative foreign currency translation gain, net of tax | $ 0.5 | |||||
Derivative, nonmonetary notional amount | MBbls | 71,900 | 71,900 | 71,900 | |||
Premium paid | 0.2 | |||||
Gain related to call options | $ 0.1 | $ 0.1 | ||||
Notional amount | € | € 20.0 |
Fair Value Measurements (Details) - USD ($) $ in Millions |
Sep. 30, 2016 |
Dec. 31, 2015 |
---|---|---|
Assets: | ||
Deferred compensation assets | $ 6.4 | $ 6.8 |
Foreign currency contracts | 0.6 | 0.2 |
Total assets at fair value | 7.0 | 7.0 |
Liabilities: | ||
Contingent consideration | 7.8 | 6.0 |
Deferred compensation liabilities | 6.8 | 8.8 |
Interest rate swap contracts | 1.3 | 2.0 |
Foreign currency contracts | 0.1 | 0.2 |
Total liabilities at fair value | 16.0 | 17.0 |
Level 1 [Member] | ||
Assets: | ||
Deferred compensation assets | 6.4 | 6.8 |
Total assets at fair value | 6.4 | 6.8 |
Liabilities: | ||
Deferred compensation liabilities | 6.8 | 8.8 |
Total liabilities at fair value | 6.8 | 8.8 |
Level 2 [Member] | ||
Assets: | ||
Foreign currency contracts | 0.6 | 0.2 |
Total assets at fair value | 0.6 | 0.2 |
Liabilities: | ||
Interest rate swap contracts | 1.3 | 2.0 |
Foreign currency contracts | 0.1 | 0.2 |
Total liabilities at fair value | 1.4 | 2.2 |
Level 3 [Member] | ||
Liabilities: | ||
Contingent consideration | 7.8 | 6.0 |
Total liabilities at fair value | $ 7.8 | $ 6.0 |
Fair Value Measurements (Details 1) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
|
Level 3 Fair Value Measurements [Roll Forward] | ||
Balance, beginning of period | $ 6.0 | $ 5.0 |
Increase in fair value recorded in earnings | 1.9 | 0.8 |
Payments | (0.1) | (0.1) |
Balance, end of period | $ 7.8 | $ 5.7 |
Fair Value Measurements (Details 2) - USD ($) $ in Millions |
Sep. 30, 2016 |
Dec. 31, 2015 |
---|---|---|
Other Financial Instruments [Abstract] | ||
Long-term debt, fair value | $ 240.4 | $ 225.0 |
Long-term debt | $ 228.6 | $ 228.9 |
Other Expense (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
Other Income and Expenses [Abstract] | ||||
Severance and post-employment benefits | $ 1.4 | $ 7.8 | ||
Asset-related charges | 0.9 | 15.9 | $ 0.0 | |
Total restructuring and related charges | 2.3 | 23.7 | ||
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements | 0.0 | $ 49.0 | 0.0 | 49.0 |
Executive retirement and related costs | 0.0 | 10.9 | ||
Venezuela currency devaluation | 2.7 | |||
Development income | (0.4) | (0.3) | (1.2) | (1.1) |
Contingent consideration costs | 0.0 | 0.5 | 1.9 | 0.8 |
Other items | 0.6 | (0.5) | 2.0 | (1.5) |
Total other expense | $ 2.5 | $ 48.7 | $ 29.1 | $ 58.1 |
Other Expense (Details 1) $ in Millions |
3 Months Ended | 9 Months Ended | |||||
---|---|---|---|---|---|---|---|
Sep. 30, 2016
USD ($)
|
Sep. 30, 2015
USD ($)
|
Sep. 30, 2016
USD ($)
|
Sep. 30, 2015
USD ($)
|
Feb. 17, 2016 |
Dec. 31, 2015 |
Sep. 30, 2013
USD ($)
|
|
Other Income and Expenses [Abstract] | |||||||
Share-based compensation, new LTIP award | $ 2.4 | ||||||
Share-based compensation, plan modification & accelerated compensation cost | 8.0 | ||||||
Other retirement related costs | 0.5 | ||||||
Development income | $ (0.4) | $ (0.3) | $ (1.2) | (1.1) | |||
Nonrefundable payment from customer | 14.8 | 14.8 | $ 20.0 | ||||
Unearned income, current | 1.5 | 1.5 | |||||
Unearned income, noncurrent | 13.3 | 13.3 | |||||
Summary of Investment Holdings [Line Items] | |||||||
Venezuela currency devaluation | 2.7 | ||||||
Executive retirement and related costs | $ 0.0 | $ 10.9 | |||||
VENEZUELA | |||||||
Summary of Investment Holdings [Line Items] | |||||||
Foreign currency exchange rate, remeasurement | 10.0 | 6.3 | |||||
Net monetary assets | 3.9 | 3.9 | |||||
Cash and cash equivalents | 2.9 | 2.9 | |||||
Non-monetary assets | 1.4 | 1.4 | |||||
Estimate of possible pre-tax charge | $ 6.0 | $ 6.0 |
Other Expense (Details 2) $ in Millions |
3 Months Ended | 9 Months Ended |
---|---|---|
Sep. 30, 2016
USD ($)
|
Sep. 30, 2016
USD ($)
|
|
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and related charges | $ 2.3 | $ 23.7 |
Severance charges | 1.4 | 7.8 |
Asset impairment charges, trademark | 10.0 | |
Asset impairment charges, patent and equipment | 5.9 | |
Restructuring Reserve [Roll Forward] | ||
Balance, December 31, 2015 | 0.0 | |
Charges | 23.7 | |
Cash payments | (1.6) | |
Non-cash asset-write-downs | (15.9) | |
Balance, March 31, 2016 | 6.2 | 6.2 |
Minimum [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and related charges, expected | 25.0 | 25.0 |
Maximum [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and related charges, expected | 28.0 | 28.0 |
Severance and benefits [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and related charges, expected | 8.0 | 8.0 |
Restructuring Reserve [Roll Forward] | ||
Balance, December 31, 2015 | 0.0 | |
Charges | 7.8 | |
Cash payments | (1.6) | |
Non-cash asset-write-downs | 0.0 | |
Balance, March 31, 2016 | 6.2 | 6.2 |
Asset-related charges [Member] | ||
Restructuring Reserve [Roll Forward] | ||
Balance, December 31, 2015 | 0.0 | |
Charges | 15.9 | |
Cash payments | 0.0 | |
Non-cash asset-write-downs | (15.9) | |
Balance, March 31, 2016 | 0.0 | 0.0 |
Asset-related charges [Member] | Minimum [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and related charges, expected | 17.0 | 17.0 |
Asset-related charges [Member] | Maximum [Member] | ||
Restructuring Cost and Reserve [Line Items] | ||
Restructuring and related charges, expected | $ 20.0 | $ 20.0 |
Income Taxes (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
Income Tax Disclosure [Abstract] | ||||
Tax expense (benefit) | $ 14.4 | $ (6.6) | $ 38.3 | $ 15.1 |
Income Tax Benefit Related to Pension Settlement | 17.9 | |||
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements | $ 0.0 | (49.0) | $ 0.0 | (49.0) |
Effective tax rate | 29.30% | 28.10% | ||
Income Tax Benefit Executive Retirement & Related Costs | 4.0 | |||
Executive retirement and related costs | $ 0.0 | $ 10.9 | ||
Current income tax benefit, restructuring | $ 0.7 | $ 8.1 | ||
Current Foreign Tax Expense (Benefit) | 0.3 | |||
Restructuring and related charges | $ 2.3 | $ 23.7 |
Segment Information (Details) $ in Millions |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||
---|---|---|---|---|---|
Sep. 30, 2016
USD ($)
|
Sep. 30, 2015
USD ($)
|
Sep. 30, 2016
USD ($)
|
Sep. 30, 2015
USD ($)
|
Dec. 31, 2015
segment
|
|
Segment Reporting [Abstract] | |||||
Number of reportable segments | segment | 2 | ||||
Restructuring and related charges | $ 2.3 | $ 23.7 | |||
Venezuela currency devaluation | 2.7 | ||||
Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements | 0.0 | $ (49.0) | 0.0 | $ (49.0) | |
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||||
Net sales | 376.7 | 344.5 | 1,126.8 | 1,040.1 | |
Total operating (loss) profit | 51.3 | (3.5) | 142.5 | 83.4 | |
Interest expense | 2.2 | 3.7 | 6.7 | 11.2 | |
Interest income | 0.2 | 0.5 | 0.8 | 1.3 | |
Income before income taxes | 49.3 | (6.7) | 136.6 | 73.5 | |
Executive retirement and related costs | 0.0 | 10.9 | |||
Proprietary Products [Member] | |||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||||
Net sales | 298.1 | 269.3 | 899.9 | 821.5 | |
Total operating (loss) profit | 57.5 | 49.5 | 185.6 | 161.3 | |
Contract-Manufactured Products [Member] | |||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||||
Net sales | 79.0 | 75.5 | 227.8 | 219.4 | |
Total operating (loss) profit | 8.9 | 8.3 | 25.6 | 22.7 | |
Intersegment sales elimination [Member] | |||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||||
Net sales | (0.4) | (0.3) | (0.9) | (0.8) | |
Corporate [Member] | |||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||||
Total operating (loss) profit | (12.8) | (12.3) | (42.3) | (40.7) | |
Other unallocated items [Member] | |||||
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items] | |||||
Total operating (loss) profit | $ (2.3) | $ (49.0) | $ (26.4) | $ (59.9) |
&UL?5/!;MP@$/T5Q <$+]XTR Q8/VC3V&6*
MQP+4(/D ^D>)W-2LL*UL5#'Q+% Y,GA9"*T-+63CY&[PL
M!M["#ZY;T1MR1NON3SCE!M&"BY(^N"R=>Z7K0D)C_?23F^OYXLX+B\/U&:[_
M!>5?4$L#!!0 ( (9R7TG(J5R2L0$ !<$ 9 >&PO=V]R:W-H965T
M
?=T;[#X,ZQ[NZYZCSV@A06H=]+7] J22@64/
M]V7/L?5_O@2I0J,GU^ILI'-2'NM#4F7LZ*5@8J/6&6T/8F]8;,2U\26:KA$P
MON$'M^:8]7 ?S\[)D?Q(RF-:5,8'97S[7V_2#Y0RPKGSYC6-$S]:MB\9.3#Q
M&/#GLCEL-2^,GN]GQ_8 &_\#4$L#!!0 ( (9R7TF9>QW&H@, )D3 9
M >&PO=V]R:W-H965T[?DX-\X?Y/W?+D2/'P!*V%=)%5#X^
MV(8EB?14]OQ7.?WJ4QK>OU^]?Z_"+8?_%A5LPY,_\4X
*%7/6Z8T?XP]2Q:34Z2&.OC6]N):4!
MJQ@M5AC5]C6/ 8?*N.G&SE6XX"$PLKL\U_&?D7T!4$L#!!0 ( (9R7TD1
MWI.0"P, *8, 9 >&PO=V]R:W-H965T
5VS#)TJ025Z=JEOO,]*Y""ZK6
M9J<'S5*89ZIVM1K]3,.0)OZG3M1B5@T&]S X'D(V8PCJ$+X2T*G D(H5'C/,
MA@QK #*W1#S/\OHPRT!H")8K-/'AH%P1G(" "8A)0 8)K&*N&DQD,*7!4()Q
M-+/69?,<-Q!$04$4$&15;4-'1%$0XUYQ!SP1R!,!//8"-IAYGR?TXHGIQ"!-
M/*8A@443CV@0]L()FAE(,P-HD$4#83!,,@=)YD""T"*!, 0FT88).4 I+"W
M&@B:V/AHPFD0D&+D(Q!H8I\AT$M>$ 926#OMM07%_3T0>%.%@[T A6,B&MC>
M&8Z(B!=9W@: 0ANT 4"(>,B>V!B%R>3$8(]"@$G1"3]'L*L@^O]&B6##0(!C
M4&P7)1I9$T(DF#)U!)L& ER#VF\:&MM&%'@]\QXRP;Z! %.@Q-XSL_&D;#&/
M($,AL+<@P#CHZ*V'0!.KB&%WP8!Q4/N#!X+LC] 3T% ,;$$8LK)VMD*IU- W>00C)E?; 4^_F2?TT=#6
M)2*4<;2@$YJ*6-W!5^$73#@(B'@=$1(/O8HZ574';(_>"/0L:>G'%6E\5DDN
M[_)ZCA;3",.'B*+FV1_K;$KH0:=7\4HVO)_>2 9BE"P2$! !'M^C%_H"6.$B
MGB8U&79@$>RH[Z&KL!_M\@$MXA4O0@PE,!YN!EPVG )N6P]_QY6